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ABSTRACT 
Polyglutamine disease is a group of human hereditary neurodegenerative disease 
caused by the expansion of the existing polyglutamine domain in the disease proteins. To 
date, there are nine polyglutamine diseases identified including spinal and bulbar muscular 
atrophy, Huntington's disease and several types of spinocerebellar ataxias. Characteristics of 
polyglutamine diseases include dementia, motor dysfunction and late-onset progressive 
neurodegeneration. Formation of nuclear inclusions (NIs), the SDS-insoluble protein 
complex, in specific neurons is also a cellular hallmark of most polyglutamine diseases. 
Besides the polyglutamine disease proteins, a number of cellular proteins are also found in 
NIs such as transcriptional regulators and molecular chaperones. It is speculated that the 
recruitment of these proteins into NIs would compromise their normal cellular activities and 
thus contribute to neuronal cell dysfunction and death. Thus, identifying NI proteins would 
be a viable approach to uncover new pathogenic pathways. Using a proteomic approach, 81 
NI protein candidates were identified. Most of them are newly identified NI proteins with 
diverse cellular roles and involved in a wide range of cellular processes such as apoptosis, 
energy metabolism and signaling pathways. The recruitment of such a wide range of cellular 
proteins into the NIs would result in impairment of multiple cellular pathways and 
contribute to polyglutamine pathogenesis. The NI protein candidates further characterized in 
this study include receptor of activated protein kinase C (RACKl), alcohol dehydrogenase 
(Adh), Warts among others. For RACKl, the reduction of RACKl protein level in 
polyglutamine flies suggested that the impairment of protein kinase C (PKC) activity and 
PKC signaling pathway would be a potential polyglutamine pathogenic pathway. Besides, 
Adh activity was found to reduce in polyglutamine flies, which could be partially rescued by 
overexpression of heat shock protein 70 (Hsp70). Moreover, Warts was found to be a 
modifier of polyglutamine diseases. To conclude, the proteomic approach is promising for 
i 
identification of new NI proteins and discovery of new polyglutamine disease modifiers and 
novel pathogenic pathways, which would give a better understanding of the polyglutamine 





疾病被發現,包括延髓肌萎縮症（Spinal and bublar muscular atrophy)�亨汀頓氏舞蹈症 
(Huntington' s Disease ； HD)�以及幾類小腦脊髓幹運動失調症（Spinocerebellar ataxia)� 
聚麩胺酸疾病的特徵包括癡呆症，運動失調，以及漸進性後起始神經退化。除此以外， 
聚麩胺酸疾病的另一個顯著的特徵便是多醯胺麩胺酸蛋白質在核內聚集累積形成內容 
物（nuclear inclusions, NIs )�NIs是一種不能被十二院基硫酸鈉 (SDS)溶解的蛋白質 
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1.1 Neurodegeneration and triplet repeat diseases 
Neurodegeneration refers to the malfunctioning or loss of neurons. The brain and 
spinal cord are composed of billions of neurons that perform various functions, such as 
coordinating movement, processing sensory information and making decisions. Unlike 
many cell types in the rest of the body, neurons are not readily regenerated (Small, 2005). 
Therefore, excessive neuronal damage or loss may have devastating effects on an 
individual. Common neurodegenerative diseases include Alzheimer's disease, Parkinson's 
disease, multiple sclerosis and the triplet repeat diseases (Zoghbi and Orr, 2000). 
Neurodegenerative diseases are usually characterized by loss of memory and mobility due 
to neuronal cell death (Perutz, 1999; Zoghbi and Orr, 2000). Although much progress 
toward understanding neurodegenerative diseases has been made in recent years, few 
effective treatments are currently available. 
Triplet repeat diseases are caused by the expansion of the unstable trinucleotide 
repeats in the genome (Fu et aL, 1991; La Spada et al., 1991). Since its discovery, the 
number of triplet repeat diseases being reported is increasing, as is the complexity of its 
molecular pathology. Broadly, the triplet repeat diseases fall into two distinct classes. The 
first class is the diseases caused by the expanded trinucleotide repeat in the untranslated 
region of the genes, examples of the member include the spinocerebellar ataxias 8 and 
Fragile X syndrome (Everett and Wood, 2004). The second class is the diseases caused by 
the expansion of the trinucleotide repeat in the translated region of the genes. 
Polyglutamine diseases belong to this second class of triplet repeat disease (Everett and 
Wood, 2004). 
1 
1.2 Polyglutamine diseases 
Polyglutamine diseases are caused by the expansion of the existing glutamine-coding 
trinucleotide repeats (CAG) in the genome (Zoghbi and Orr, 2000). This in turn results in 
an expansion of the polyglutamine repeats in the respective disease proteins. The exact 
molecular mechanisms of such trinucleotide repeat expansion still remain elusive. 
To date，there are at least nine polyglutamine diseases being identified including 
spinal and bulbar muscular atrophy (SBMA), Huntington's disease (HD), dentatorubral 
and pallidoluysian atrophy (DRPLA) and several types of spinocerebellar ataxias (SCAs) 
including spinocerebellar ataxia 1, 2，3, 6, 7 and 17 (Zoghbi and Orr, 2000). Except SBMA, 
these polyglutamine disorders are dominantly inherited (Zoghbi and Orr, 2000). 
All polyglutamine disorders are progressive, typically striking in midlife and cause 
neuronal dysfunction 10-20 years after onset of disease symptoms (Zoghbi and Orr, 2000). 
There are several featured characteristics for this group of diseases. The greater the number 
of the expanded glutamine repeats, the earlier the age of disease onset and the more severe 
the disease (Zoghbi and Orr, 2000). For most of the polyglutamine diseases, the pathogenic 
threshold length of glutamine repeats is around 40 (Gusella and MacDonald, 2000; Zoghbi 
and Orr, 2000). Besides, successive generations of the affected families would experience 
an earlier age of disease onset and more rapid disease progression, due to the expansion of 
the glutamine repeats during paternal transmissions. The features of the disease-causing 
genes, their protein products, and the brain regions characteristically affected in each of the 
polyglutamine diseases are summarized in table 1 (Zoghbi and Orr, 2000). 
There are several common clinical and histopathological features shared among 
different members of polyglutamine diseases. Patients usually suffer from progressive 
neuronal cell death, resulting in loss of neuronal function, motor control, and in some cases 




































































































































































































































































































































































































































































































































































































































most neurons, neuronal degeneration is only observed in specific brain regions and 
neuronal cell types (Schilling et aL, 1995; Zoghbi and Orr, 2000). 
The most remarkable histopathological feature of polyglutamine diseases is the 
existence of microscopically discernible protein aggregation or inclusions of the expanded 
polyglutamine proteins in specific neurons (Fig. 1) (Schilling et al.，1995; Paulson et aL, 
1997; Becher et al., 1998; Li et aL, 1998b; Li et al., 1998a; Ross and Poirier, 2004). 
Besides, the protein inclusions are usually found in the nucleus, therefore called as nuclear 
inclusions (NIs) (Zoghbi and Orr, 2000). NIs are SDS-insoluble protein complex which are 
heterogeneous in nature (Hazeki et aL, 2000). Besides the expanded polyglutamine disease 
proteins, a number of essential cellular proteins are also found in NIs such as 
transcriptional regulators, proteosome components and molecular chaperones (Suhr et al., 
2001; Mitsui et al , 2002; Doi et al., 2004). 
1.3 Polyglutamine nuclear inclusions 
The presence of NIs in affected neurons is a unifying pathological feature of 
polyglutamine diseases. Besides, it has been suggested that NIs are critical to the disease 
pathogenesis (Davies et al., 1997; Margolis and Ross, 2001). In view of this, how NI 
formation contributes to polyglutamine pathogenesis becomes an interesting topic being 
intensively studied. 
1.3.1 Kinetics of polyglutamine nuclear inclusion formation 
It was suggested that the expanded polyglutamine proteins acquired a novel tendency 
to form NIs (Perutz, 1994; Scherzinger et al.，1997; Chen et al., 2001). Some studies 
showed that NIs could be reproduced in vitro by overexpressing the expanded Huntingtin 
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Figure 1. Formation of nuclear inclusions (NIs) in polyglutamine disease patients. 
A unifying pathological feature of polyglutamine disease is the presence of 
microscopically discernible NIs of the expanded polyglutamine proteins in the 
nucleus of affected neurons of polyglutamine disease patients. The picture shown is 
the formation of NIs (shown by the white arrow) in the neurons of a spinocerebellar 
ataxia-1 patient. (Adapted from Zoghbi and Orr, 2000, Annu. Rev. Neurosci. 23:217-
247) 
Figure 2. The Polar Zipper model of polyglutamioe nuclear inclusions. 
The computer-generated model shows the formation of P-sheet structure within 
the expanded polyglutamine proteins. The expanded polyglutamine tract is held 
side-by-side by hydrogen bonds (the dotted lines) resulting in the formation of 
hairpin loop and hence aggregation of the expanded polyglutamine proteins. 
Color codes: light blue for carbon, dark blue for nitrogen, red for oxygen. 
(Adapted from Ross & Poirier’ 2004, Nature Medicine 10: SIO - SI7) 
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proteins or synthetic polyglutamine peptides in cells (Pemtz, 1994; Scherzinger et al•，1997; 
Chen et al., 2001), implying that the expanded polyglutamine tract itself is sufficient for 
triggering NI formation. 
Studies found that NI formation displayed kinetics of nucleated-growth 
polymerization, with a prolonged lag-phase required to form the NI nucleus, followed by a 
fast extension phase during which additional polyglutamine monomers rapidly join the 
growing NIs (Scherzinger et al , 1999; Chen et a l , 2001). Theoretically, the propensity of 
expanded polyglutamine proteins to form NIs should derive from its ability to self-interact. 
Researchers used molecular modeling to reveal the molecular details of the self-interaction 
of polyglutamine proteins and yielded a number of plausible structures (Pemtz et al., 1994; 
Lathrop et a l , 1998; Starikov et al., 1999; Thakur and Wetzel, 2002). The most popular 
model is the 'polar zipper' model put forward by Max Pemtz. It was suggested that when 
polyglutamine repeats longer than certain critical length, the expanded polyglutamine 
proteins form highly stable intra-molecular B-sheet structure by creation of hairpin loop 
(Fig. 2) (Pemtz et al., 1994). Besides, many expanded polyglutamine proteins would join 
together by forming inter-molecular B-sheet, leading to rapid protein aggregation which 
serves as a seed for NI formation (Pemtz et al., 1994). During the aggregation process, the 
expanded polyglutamine proteins also interact with other cellular proteins and recruit them 
into the NIs, perhaps through the interaction between polyglutamine tracts (Pemtz et al., 
1994). Yet, the precise organization of polyglutamine NIs and the mechanisms of how NIs 
ended up in the nucleus still remains a subject of intensive study. Besides, in vitro analysis 
demonstrated that above the pathological threshold length of polyglutamine repeats, longer 
polyglutamine tracts display more rapid NI nucleation (Scherzinger et al, 1999; Chen et al., 
2002). Hence, it was suggested that NI formation would take place sooner in patients with 
6 
longer polyglutamine repeats, probably explaining the earlier onset of disease symptoms in 
these patients (Scherzinger et al., 1999; Chen et al., 2002). 
1.3.2 Roles of protein inclusions in neurodegeneration 
Indeed, the formation of abnormal cellular protein inclusions is a hallmark of a large 
group of neurodegenerative diseases, known as the protein conformation diseases. Besides 
polyglutamine disease, other members of this group of diseases include Alzheimer's 
disease, Parkinson's disease, and prion disease among others (Zoghbi and Orr, 2000). 
However, the mechanisms by which protein inclusions induce neurodegeneration still 
remain controversial. It is not certain whether the protein inclusions are pathogenic, or just 
represents the end products of upstream toxic events, or even serve as a protective role 
(Saudou et al , 1998; Michalik and Van Broeckhoven, 2003; Everett and Wood, 2004). 
Nevertheless, there are several lines of evidence which support the pathogenic role of the 
polyglutamine NIs. Some studies showed that shutting down the expression of expanded 
Huntingtin protein in a HD mouse model led to disappearance of NIs and amelioration of 
the polyglutamine behavioral phenotype (Yamamoto et al., 2000). Moreover, polypeptides 
binding to expanded Huntingtin protein were able to interfere with NI formation in a HD 
fly model, with a reduction in polyglutamine toxicity and lethality (Apostol et al., 2003). 
These studies suggest the toxic gain-of-function of the expanded polyglutamine proteins 
and the pathogenic role of NIs in polyglutamine diseases. 
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1.4 Polyglutamine pathogenic pathways 
A great deal of efforts has been made to reveal the detailed pathogenic mechanisms of 
polyglutamine diseases. Various methods have been adopted to study polyglutamine 
diseases such as microarray (Chan et al., 2002a; Luthi-Carter et al., 2002; Sipione et al., 
2002) and genetic modifier screen (Kazemi-Esfarjani and Benzer，2000; Faber et al., 2002; 
Kazemi-Esfarjani and Benzer, 2002). Previous studies found that the molecular 
mechanisms of polyglutamine disease are complex (Zoghbi and Orr, 2000; Michalik and 
Van Broeckhoven, 2003). Nevertheless, some pathogenic pathways have been proposed 
such as dysregulation of transcriptional regulation, impairment of protein degradation 
machinery and activation of apoptotic pathways (Michalik and Van Broeckhoven, 2003; 
Lipinski and Yuan, 2004; Ross and Poirier, 2004). 
Toxic gain-of-function of expanded polyglutamine proteins 
Numerous observations argue convincingly that expanded polyglutamine protein by 
itself elicits dominant gain-of-function neurotoxicity in polyglutamine diseases. First, with 
the exception of SBMA, all polyglutamine diseases are autosomal dominant. Second, 
expression of the expanded polyglutamine proteins in transgenic mice harbouring two 
intact copies of their respective wild-type alleles still provoked neuronal dysfunction and 
neurodegeneration (Burright et al, 1995; Reddy et al., 1998; Schilling et al., 1999; Yvert et 
al., 2000). Third, expanded polyglutamine disease proteins also induced neurodegeneration 
in Drosophila and C. elegans, which lack functional homologues of the polyglutamine 
disease proteins (Jackson et al., 1998; Warrick et al., 1998; Faber et aL, 1999; Femandez-
Funez et al., 2000). Finally, expanded polyglutamine proteins induces neuronal toxicity in 
transgenic models even if the polyglutamine tracts was carried by proteins entirely 
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unrelated to the polyglutamine proteins (Ordway et al., 1997), or when expressed without 
any adjoining protein sequences (Kazemi-Esfarjani and Benzer, 2000; Marsh et al., 2000; 
Adachi et al., 2001). Therefore, these studies suggest the toxic gain-of-function of the 
expanded polyglutamine proteins. 
1.4.1 Protein depletion theory 
Some studies proposed that the formation of NIs would be a major contributor to the 
dominant toxicity of the expanded polyglutamine proteins (Davies et al., 1999; Marsh et al., 
2000). Then how can NIs trigger the dominant toxicity of expanded polyglutamine? The 
protein depletion theory provides a possible explanation for such correlation. 
It is found that a number of other important cellular proteins are present in the NIs 
besides the expanded polyglutamine disease proteins, such as transcriptional regulators, 
proteasome components and molecular chaperones (Suhr et al., 2001; Mitsui et al., 2002; 
Doi et al., 2004). Since such a wide range of cellular proteins are sequestered into the NIs, 
it is speculated that their recruitment into the NIs would compromise their normal activities 
and eventually contribute to cellular disturbance and neuronal cell death of polyglutamine 
diseases. This hypothesis is widely known as the 'protein depletion theory' (Yamada et al., 
2000; Fischbeck, 2001; Michalik and Van Broeckhoven, 2003; Everett and Wood, 2004). 
Hence, what kinds of proteins are sequestered into the polyglutamine NIs, and what 
molecular forces mediate their interaction with the polyglutamine disease proteins are 
critical in revealing the disease pathogenesis. 
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Dysregulation of gene transcription 
A variety of glutamine-rich transcriptional regulators were found in polyglutamine 
NIs, including the cAMP response element binding protein binding protein (CBP) in HD, 
SCA3, SCA7 and DRPLA (McCampbell et al , 2000; Steffan et al., 2000), the TATA-
binding protein (TBP) in SCA3 (Perez et al., 1998), the TBP-associated factor (TAFulBO) 
in DRPLA (Shimohata et al., 2000), and the specificity protein 1 (Spl) in HD (Shimohata 
et al , 2000). It was suggested that the presence of short glutamine repeats in most 
transcriptional regulators together with their preferential localization inside the nucleus 
would favor their interaction with the expanded polyglutamine proteins via glutamine— 
glutamine interactions, as well as their recruitment into the NIs (Michalik and Van 
Broeckhoven, 2003). It is suggested that the recruitment of these important transcriptional 
regulators into the NIs is responsible for the impairment of a number of transcriptional 
activities observed in polyglutamine disease models and patients (Luthi-Carter et al., 2000; 
Wyttenbach et al., 2001; Chan et al., 2002a; Luthi-Carter et al.，2002). 
For example, the transcriptional activator cyclic AMP response element binding 
protein (CREB) and its coactivator CBP are the most common transcriptional factors found 
in polyglutamine NIs (McCampbell et al, 2000; Steffan et al., 2000). The recruitment of 
CREB/CBP into the NIs and the disruption of CREB/CBP-mediated gene expression have 
been observed in HD, SCA3, SCA7，DRPLA and Kennedy's disease (McCampbell et al., 
2000; Steffan et al., 2000). Normally, CBP cooperates with the transcription factor CREB 
to activate the expression of a wide range of cAMP-responsive genes (McCampbell et al., 
2000; Steffan et al., 2000). However, most of the CREB/CBP-dependent transcriptional 
activities are disrupted in polyglutamine disease models (Walton and Dragunow, 2000), 
while overexpression of exogenous CBP in these models can restore the impaired CBP-
mediated transcriptional activities and alleviate polyglutamine toxicity (McCampbell et al, 
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2000; McCampbell et al., 2001; Nucifora et al.，2001). Therefore, it is suggested that the 
dysregulation of CREB/CBP transcriptional activity is caused by the compromised 
CREB/CBP activities due to their depletion into the NIs (McCampbell et al., 2000; 
McCampbell et al., 2001; Nucifora et al , 2001). 
Impairment of protein folding and degradation pathway 
Another group of cellular proteins commonly found in the NIs are molecular 
chaperone, proteasome components and ubiquitin. They have been observed to colocalize 
with NIs in several in vivo and in vitro polyglutamine models including HD, MJD, SCAl, 
among others (Cummings et al., 1998; Chai et al., 1999; Jana et al., 2000; Bence et al., 
2001). Molecular chaperones are a group of molecules which assist in proper protein 
folding as well as protein degradation if the proteins cannot be refolded properly (Haiti, 
1996), whereas ubiquitin and proteasome components are involved in targeting misfolded 
proteins for degradation and finally their clearance (Ardley et al., 2005). 
Why molecular chaperone, proteasome components and ubiquitin are preferentially 
recruited into the polyglutamine NIs? It is speculated that the molecular chaperones and 
protein degradation machinery are attracted into the NIs by recognizing the misfolding 
nature of the expanded polyglutamine proteins, attempting to refold the disease proteins, as 
well as targeting them for degradation if they cannot be properly refolded (Chai et al., 1999; 
Opal and Zoghbi, 2002). On the other hand, the fact that NIs are eventually formed with 
the recruitment of chaperone and proteasome machinery may imply that the misfolded 
expanded polyglutamine proteins have overwhelmed the capacity of the molecular 
chaperones (Sakahira et al., 2002a). 
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The recruitment of chaperones and protein degradation machinery into the NIs may 
also limit their availability in the cell, leading to diminished clearance and thus harmful 
accumulation of other misfolded or damaged cellular proteins. This impaired protein 
degradation machinery would in turn activate cellular stress response and apoptosis (Opal 
and Zoghbi, 2002; Sakahira et al., 2002a). It has also been suggested that when a cell 
amasses excessive aggregated polyglutamine proteins, a self-reinforcing cascade would be 
initiated. That is less free proteasome results in slower degradation of the expanded 
polyglutamine disease proteins with enhanced NI formation and further decline of free 
proteasome, which may in turn increase cellular stress and induce apoptosis in 
polyglutamine diseases (Jana et al., 2000; Bence et aL, 2001; Michalik and Van 
Broeckhoven, 2003). 
Recruitment of other cellular proteins into NIs 
Besides transcriptional regulators and the chaperone/proteasome components, other 
cellular proteins are also found in NIs such as actin, proteins of the nuclear pore complex, 
p53 and glyceraldehyde-3-phosphate dehydrogenase (Suhr et al., 2001; Mitsui et al., 
2002; Doi et al., 2004). These cellular proteins might be recruited into the NIs through 
interactions with the non-polyglutamine segments of the polyglutamine disease proteins 
(Hazeki et al., 2002; Mitsui et aL, 2002). Moreover, because the various polyglutamine 
disease proteins differ markedly outside of their polyglutamine tracts, NIs of different 
polyglutamine diseases would recruit distinct sets of interacting proteins. This would 
result in different cellular functions being affected, thereby adding to the phenotypic 
differences of various polyglutamine diseases. 
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1.4.2 Induction of apoptotic pathways 
Besides the protein depletion theory, other polyglutamine pathogenic pathways have 
also been proposed. It is becoming increasingly apparent that apoptosis is critical to 
neurodegeneration in polyglutamine diseases (Lipinski and Yuan, 2004). Cellular models 
of HD have shown that polyglutamine toxicity is mediated by increased sensitivity to 
apoptotic stress (Saudou et al., 1998; Kim et al., 1999). Besides, a number of studies found 
that caspases were activated in HD brain (Sanchez et al., 1999; Sawa et al , 1999). On the 
contrary, inhibition of caspases could abrogate the formation of NIs and prolong the 
survival of cells (Kim et al , 1999; Moulder et al., 1999; Wang et al.’ 1999a; Wellington et 
al., 2000). For example, inhibiting caspase-1 in HD-transgenic mice had delayed the 
appearance of NIs and the onset of polyglutamine disease symptoms (Ona et al., 1999). 
Besides, HD-transgenic mice treated with minocycline, which is known to downregulate 
caspase-1 and -3 expressions, could also delay the onset of the polyglutamine disease 
symptoms (Chen et al., 2000). Moreover, Sanchez et al. (1999) demonstrated that 
expression of the expanded polyglutamine tracts in rat neurons led to the recruitment of 
caspase-8 into the NIs, resulting in its activation. In this system, caspase-8 activity is 
necessary for polyglutamine neuronal cell death, as caspase-8 deficiency or expression of 
dominant-negative caspase-8 suppressed the neuronal cell death. Therefore, these studies 
suggested that apoptosis would be one of the pathogenic mechanisms in triggering 
neuronal cell death of polyglutamine diseases. 
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1.5 Previous study on NI proteins 
According to the protein depletion theory, identification of NI proteins would be a 
viable approach to uncover novel polyglutamine pathogenic pathways, as well as potential 
therapeutic interventions. For example, the identification of CBP as a NI protein gives us 
insight to find out the impairment of CBP-dependent transcription activity as one of the 
polyglutamine pathogenic pathways (Janknecht, 2002). Furthermore, the fact that 
polyglutamine pathogenesis could be partially suppressed by overexpression of CBP gives 
us hints that restoration of the compromised activities of NI proteins would be a potential 
intervention of polyglutamine diseases (McCampbell et al., 2000; McCampbell et al., 2001; 
Nucifora et al.,2001). 
To date, a thorough investigation of NI proteins is still lacking. Previous studies of NI 
proteins are mostly based on in vitro cell model and only a short list of candidates has been 
found (Suhr et al., 2001; Mitsui et al, 2002; Doi et al., 2004). It is suggested that the list is 
not yet saturated since different approaches found different subsets of NI proteins (Suhr et 
al., 2001; Mitsui et al., 2002; Doi et al., 2004). Although in vitro model can serve as a 
quick way for initial screening, the true cellular environment of living organisms can 
hardly be mimicked. Furthermore, those candidates found using in vitro models need to be 
confirmed in vivo. In view of this, the present study was to identify and characterize a more 
complete list of NI proteins using in vivo polyglutamine fly models. 
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1.6 Drosophila model for studying polyglutamine diseases 
1.6.1 Drosophila model for studying human diseases 
Drosophila is one of the most popular in vivo models for studying human diseases 
(Marsh et a l , 2003). Comparative genomic analysis reveals that at least 50% of fly genes 
have their human orthologes (Rubin et al., 2000). On the other way, at least 60% of human 
disease genes have their Drosophila counterparts (Reiter et al., 2001). Moreover, 
Drosophila is an ideal choice for modeling neurodegenerative diseases because it bears a 
well-developed nervous system with an architecture that separates specialized functions 
such as vision, olfaction, learning and memory in a manner similar to that of mammalian 
nervous systems (Marin et al., 2002; Rein et al., 2002; Wong et al., 2002). Furthermore, 
Drosophila compound eye is made up of some eight hundreds of repeating constellations 
of photoreceptor neurons such that any perturbation in the pattern is quite evident (Marsh 
et al., 2003). Hence, Drosophila eyes have been frequently used as a convenient 
phenotypic indicator in various studies. Besides, the dominant neurodegenerative diseases 
are particularly well suited for modeling in Drosophila because most of them are caused by 
gain-of-function mutations in single gene (Shulman et al., 2003). Such single disease gene 
can be readily engineered to express in flies (Marin et al , 2002; Rein et al., 2002; Wong et 
al., 2002). 
1.6.2 GAL4/UAS gene expression system 
Foreign human disease genes can be easily engineered to express in tissue-specific 
and/or temporally regulated patterns in Drosophila by a bipartite gene expression system 
(Fig. 3) (Brand and Perrimon, 1993). In this system, foreign genes are inserted downstream 
of the yeast upstream activator sequence (UAS). The UAS-transgenic flies are then crossed 
to the “Gal4 driver lines" that express Gal4 protein in a variety of tissue-specific patterns 
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Figure 3. The Drosophila GAL4/UAS gene expression system. Under the 
control of a genomic enhancer, transgenic GAL4 driver fly line expresses the 
yeast transcriptional activator protein GAL4 in a tissue specific manner. For the 
UAS-Gene X transgenic line, genes to be expressed (Gene X) are inserted 
behind the yeast upstream activation sequence (UAS). By crossing the GAL4 
line to the UAS-Gene X line, the GAL4 protein which expresses in a tissue 
specific manner would bind to the UAS sequence to activate the transcription of 
gene X. (Adapted from Brand and Perrimon, 1993, Development 118:401-415) 
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by fusing Gal4 gene behind different tissue-specific promoters (Duffy, 2002). In this way, 
the UAS-transgenes can be activated by the yeast Gal4 protein in a tissue specific manner. 
A large collection of 'Gal4 driver lines' is available, for example, "gmr-Gal4 line" drives 
expression of UAS-transgenes in fly photoreceptor neurons and eye pigment cells (Brand 
and Perrimon, 1993). 
1.6.3 Drosophila polyglutamine models 
Human polyglutamine disease was initially modeled in Drosophila by overexpressing 
the SCA3 human disease gene, also called the Machado-Joseph disease (MJD) gene 
(Warrick et al., 1998). Till now, other Drosophila polyglutamine disease models have been 
established by overexpressing the respective human polyglutamine disease proteins, 
including the Huntingtin protein (Htt) for HD (Jackson et aL, 1998), the ataxin-1 protein 
for SCAl (Fernandez-Funez et al, 2000) and the androgen receptor (AR) protein for 
SBMA (Takeyama et al., 2002). 
Overexpression of the pathogenic forms of MJD, Htt, ataxin-1 and AR proteins in fly 
all cause neuropathology similar to that in human patients (Bonini and Fortini, 2003). First, 
all the polyglutamine fly models exhibit a glutamine-length dependent pathology similar to 
polyglutamine disease patients, i.e. the longer the polyglutamine repeats, the earlier the 
disease onset and the more severe the disease (Bonini and Fortini, 2003). Second, when the 
expanded polyglutamine proteins are overexpressed in fly eyes by the Gmr-Gal4/UAS 
expression system, it induces progressive neuronal cell death and eye depigmentation (Fig. 
4) (Warrick et al., 1998; Chan et al., 2000). Since the external eye phenotype has found to 
highly correlate with the neuronal cell death, the eye phenotype is often used as an 
indicator for assessing the degree of neurodegeneration in polyglutamine fly models 
(Warrick et al., 1998; Chan et al, 2000). Third, formation of NIs is also observed in 
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polyglutamine fly models (Fig. 5) (Warrick et al., 1998; Chan et al , 2000). Some NI 
proteins which were found in polyglutamine patients have also been found in 
polyglutamine flies, for example the heat shock protein Hsp70 (Bonini, 2002; Sakahira et 
al., 2002b). To conclude, polyglutamine fly models exhibit characteristic disease 
pathologies that mimic human polyglutamine diseases in most important ways. Therefore, 
fly is an ideal model for studying polyglutamine diseases. 
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Figure 4. Overexpression of expanded truncated human Machado->foseph 
Disease (MJDtr) proteins in Drosophila eyes causes neuronal degeneration. The 
control transgenic flies overexpressing the GAL4 protein showed no degeneration as 
indicated by the red eye pigment (A) and intact retinal structure (C). Flies 
overexpressing the expanded MJDtrQ78s protein caused neuronal degeneration as 
indicated by loss of red eye pigment (B) and severe loss of photoreceptor cells within 
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Figure 5. Overexpression of expanded truncated human Machado-Joseph 
Disease (MJDtr) proteins in Drosophila eyes results in the formation of 
polyglutamine nuclear inclusions (NIs). 
(A-B) Iimnunostaining of larva eye disc overexpressing the unexpanded MJDtrQ27 
protein showed diffiised distribution of MJDtrQ27 in cytoplasm (A). Fly 
overexpressing the expanded MJDtrQ78s protein resulted in the formation of 
polyglutamine protein-positive NIs (white arrows, B). (Adapted and modified from 
Warrick et al.，1999，Nature Genetics 23:425-428) 
(C) Western blot analysis showed the presence of SDS-insoluble protein complex in 
the SDS-PAGE stacking gel for protein sample extracted from MJDtrQ78s flies 
(lane 2), indicating the formation of SDS-insoluble NIs. However, no such protein 
complex was detected for protein extracted from the MJDtrQ27 flies (lane 1). 
(Adapted from Chan et al.，2000, Hum Mol Genet 9:2811-2820) 
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1.7 Objectives 
The objectives of this project are to identify new nuclear inclusion proteins of 
polyglutamine disease by proteomic approach and to characterize the roles of these nuclear 
inclusion proteins in polyglutamine pathogenesis, using Drosophila polyglutamine models. 
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2. MATERIALS AND METHODS 
2.1 Drosophila genetics 
2.1.1 Drosophila culture 
Flies were raised in plastic vials containing fly food and covered with cotton. Stocks 
were kept in 25°C incubators (LMS) or at room temperature of around 20�C. Water was 
added to the vials to prevent food from drying out. For the production of fly food, a 
mixture was made by mixing 12.5 g agar, 105 g dextrose, 105 g maize and 21 g yeast in 
water and boiled for about 20 min with the addition of 80ml of 1% nipagin in ethanol, 
made up to 1 L. Then, 15 ml of fly food was aliquoted to each plastic vial. 
Female virgin flies were collected by first removing all the adult flies in the vials. 
Virgins were collected within 8 hours at 25°C or 16 hours at 18°C. All crosses were carried 
out at 25°C. For each cross, around 5 virgins and 5 male flies were put in one plastic vial 
containing fly food supplemented with dry yeast. The genotypes of fly lines used in this 
study were summarized in table 2. 
2.1.2 GAL4/UAS gene expression system 
GAL4/UAS system was used to achieve tissue specific expression of transgenes 
(Brand and Perrimon, 1993). Gmr-GAL4 driver fly line was crossed to various UAS-
transgene lines to drive transgene expression in fly photoreceptor neurons and pigment 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.1.3 Eye phenotypic analysis 
Drosophila external eye phenotype was observed using various stereo-microscopes 
(Nikon Leica, and Zeiss). Photos of external eye phenotype were captured using a CCD 
camera (Diagnostic Instruments) and the software "Advanced Spot System". 
2.1.4 Polyglutamine fly models 
The major polyglutamine fly model used in this study is the MJD model, in which 
flies overexpressed the truncated human MJD proteins with different length of glutamine 
repeats in eyes using the Gmr-Gal4/UAS expression system. The MJD model used 
including flies overexpressing the unexpanded MJDtr protein of 27 glutamine repeats 
(MJDtrQ27), of 61 glutamine repeats (MJDtrQ61) and of 78 glutamine repeats strongly 
(MJDtrQ78s) (Warrick et al., 1998). Other fly models were also used such as the SBMA 
and SCAl models. The SBMA models used are flies weakly or strongly overexpressing the 
truncated human androgen receptor protein of 112 glutamine repeat (ARtrQ112w, 
ARtrQ112s) and of 16 glutamine repeats (ARtrQ16) (Takeyama et al., 2002). The SCAl 
models used are flies overexpressing the full-length human ataxin-1 proteins of 82 
glutamine repeats (SCA1Q82) and of 30 glutamine repeats (SCA1Q30) (Fernandez-Funez 
et al., 2000). The genotypes of these polyglutamine fly lines were summarized in table 2. 
2.1.5 Generation and characterization of GFP-polyglutamine 
transgenic fly models 
Transgenic fly lines overexpressing UAS-GFP-polyQ-FLAG fusion proteins (UAS-
GFP-Q28-FLAG and UAS-GFP-Q76-FLAG) were generated. The addition of the GFP 
moiety to the polyglutamine peptide is to allow direct visualization of the polyglutamine 
NIs, whereas the FLAG epitope can be used for immunodetection of the polyglutamine 
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fusion protein. For generating transgenic flies, the constructs of UAS-GFP-Q28-FLAG 
and UAS-GFP-Q76-FLAG were generated by Miss Echo Chen (Department of 
Biochemistry, CUHK) and sent for microinjection. The transgenic flies were then 
characterized for the expression of trans genes by observing the external eye phenotype of 
the progenies and detecting the expression of transgenes by Western blotting. 
2.2 Proteomic identification of nuclear inclusion proteins 
2.2.1 Proteomic identification of NI proteins by SDS-insolubility of 
NIs 
It has been shown that the NIs complex are SDS-insoluble and trapped in the stacking 
gel (Chan et al., 2000). As an initial attempt to identify NI proteins, I made use of the SDS-
insolubility properties of NIs. The stacking gel was cut out for trypsin in-gel digestion and 
subjected to mass spectrometry analysis for identification of the protein contents inside the 
stacking gel. This method was named as stacking gel approach. 
Fly heads overexpressing polyglutamine disease proteins of MJDtrQ61 were cut 
and homogenized in 6X protein sample buffer (section 2.9). The samples were then boiled 
at 99°C for 2 min and load into SDS-PAGE gel. Since NIs are SDS-insoluble, they are 
trapped in the SDS-PAGE stacking gel while other cellular proteins are separated into the 
running gel. The stacking gel containing the NI protein complex was cut out for trypsin in-
gel digestion (section 2.2.2.6). The digested product was then subjected to mass 
spectrometry analysis for protein identification. 
26 
2.2.2 Proteomic identification of NI proteins by FA-solubility of 
NIs 
2.2.2.1 Approach overview 
Since NIs are SDS-insoluble, they cannot be separated into the SDS-PAGE resolving 
gel (Chan et al., 2000). However, previous studies showed that NI protein complex can be 
dissolved by formic acid (FA) (Hazeki et aL, 2000). Therefore, NI protein complex was 
dissolved by FA into individual protein monomer and hence separated by SDS-PAGE. By 
comparing the FA-treated and -untreated 2D gels, those differential protein spots only 
present or with higher intensity in the FA-treated gel should correspond to the potential NI 
proteins. This method was named as "2D approach". The principle of the approach was 
illustrated in figure 6. 
2.2.2.2 Sample preparation for two-dimensional gel electrophoresis 
One hundred fly heads overexpressing the unexpanded MJDtrQ27 protein or the 
expanded MJDtrQ61 protein were cut and homogenized in 150 |il of lysis buffer (section 
2.9). Head extracts without head debris were subjected to ultra-centrifugation (Beckman) 
at 100,000 rpm for 60 min at 4°C. Pellets containing the NIs and other large cellular 
proteins were subjected to FA treatment to solubilize NIs (Hazeki et al., 2000). Pellets were 
resuspended with 80 \x\ of 100% FA and incubated for 60 min at room temperature. Since 
the FA-treated samples were too acidic for loading into SDS-PAGE, FA was first removed 
from the samples by SpeedVac set at low drying rate. The pellets were then resuspended in 
80 |il of 2D rehydration buffer (section 2.9). The protein extracts were then desalted and 
precipitated with trichloroacetic acid (TCA). In brief, equal volume of 20% TCA was 
mixed to the samples and incubated at -80°C overnight. The samples were then centrifuged 
at 14,000 rpm at 4°C for 45 min. The supernatant was then removed and the pellets were 
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Figure 6. Identification of polyglutamine nuclear inclusion proteins by the “2D approach". 
MJDtrQ61 fly heads were cut and homogenized in lysis buffer and subjected to ultra-
centrifugation for fractionation of the large protein complex of NIs. Pellets containing NIs and 
other large cellular proteins were treated with formic acid (FA) for solubilization of NIs (gel B) 
or treated with SDS-buffer for control (gel A). Since NIs are SDS-insoluble, they cannot be 
separated into the SDS-PAGE mnning gel (gel A). However, NI proteins can be dissolved into 
individual protein monomers by FA and separated into the running gel (gel B). Therefore, by 
comparing the 2D gels, differential protein spots that are only present or with higher intensity in 
the FA treated gel (gel B) would correspond to the NI protein candidates. The red spots represent 
NI proteins while the brown spots represent other non-NI cellular proteins. 
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washed with 400 jil of ice-cold acetone. The pellets were recovered by centrifugation at 
14,000rpm for 45 min at 4�C. The washing step was repeated twice. The pellets were 
finally resuspended in 230 |il of 2D rehydration buffer and stored at -20°C until use or 
directly used for 2D gel electrophoresis. 
2.2.2.3 Two-dimensional gel electrophoresis 
First-dimension isoelectric focusing 
First-dimension isoelectric focusing (lEF) was performed on the Ettan IPGphor II 
isoelectric focusing system (GE Biosciences). Prior to loading to the strip holder, 15 fil of 
IM dithiothreitol (DTT) and 1.25 jil of Pharmalyte pH3-10 (GE Biosciences) were added 
to each protein sample, and made up to a total volume of 250 jil. The entire 250 |il of 
samples were evenly loaded along the 13 cm strip holder (GE Biosciences). The IPG strip 
(PH 3-10) (GE Biosciences) was then placed onto the strip holder with the gel face facing 
downward and polarity matched to the strip holder (acidic end of the strip matched to the 
cathode of the holder). IPG cover fluid was then added on top of the strip to minimize 
evaporation and urea crystallization. The holder was covered with a lid and placed onto the 
Ettan IPGphor II isoelectric focusing unit. Isoelectric focusing was performed overnight at 
20°C. The current was limited to 50 l^A per strip and the program used was as follows: 
Step 1 Step-and-hold 30V 390 Vhr 
Step 2 Gradient 500V 250 Vhr 
Step 3 Gradient lOOOV 500 Vhr 
Step 4 Gradient 3000V 1,500 Vhr 
Step 5 Gradient 5000V 2,500 Vhr 
Step 6 Step-and-hold 8000V 16,000 Vhr 
Total Vhr �20,000 Vhr 
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Second-dimension gel electrophoresis 
After first-dimension lEF, the strips were removed from the strip holder, first 
equilibrated with 10 ml of equilibration buffer containing dithiothreitol (DTT) (section 2.9) 
for 15 min and then with 10 ml equilibration buffer containing iodoacetamide (lAA) 
(section 2.9) for another 15 min. After equilibration, the strips were subjected to second-
dimension gel electrophoresis using Protean II XI Cell (Bio-RAD) with the gel size of 16 
cm X 20 cm. The glass plate sandwiches were assembled according to the manufacturer's 
instruction using 1 mm spacer. 12 % polyacrylamide resolving gel solution (section 2.9) 
was prepared and loaded to the gel cassette. Isopropanol was added to the top of the gel to 
keep the gel solution out of atmospheric oxygen and to remove bubbles. After the gel 
solution polymerized completely in about 30 min, isopropanol was poured off and the gel 
surface was washed with dHiO. The equilibrated 2D strip was then put on top of the 
resolving gel. About 6 \x\ of broad range prestained SDS-PAGE standards protein marker 
(Bio-RAD) was first soaked in a small piece of filter paper and placed at the top comer of 
the resolving gels. The strips and the filter paper were then fixed by applying about 1 ml of 
the pre-melted sealing solution (section 2.9) onto the strips. After the sealing solution was 
set, the glass plate sandwiches were then assembled onto the cooling core and the whole 
set was put into the tank. The upper buffer chamber was filled with fresh SDS-
electrophoresis buffer (section 2.9) and the outer chamber with fresh or re-used buffer. The 
cooling core was then connected to running water as cooling system. Electrophoresis was 
performed at constant voltage of 180 V for about 8 hr until the blue dye front reached the 
bottom of the gel. The gels were stained by Coomassie Brilliant Blue or silver stain (GE 
Biosciences). 
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2.2.2.4 Polyacrylamide gel staining 
Coomassie Brilliant Blue staining 
After electrophoresis, the gel was immersed in staining solution containing 0.25 % 
Coomassie Brilliant Blue R250, 45 % methanol and 10 % acetic acid overnight at room 
temperature with continuous shaking. The gel was then destained with solution containing 
45 % methanol and 10 % acetic acid until the destaining was completed. After that, the gel 
was equilibrated in dHiO. 
Silver staining 
Silver staining was done using Silver Staining Kit (Amersham Biosciences). The 
staining was done according to the manufacturer's protocol. All the solutions were 
prepared freshly using the powders and solutions provided in the kit. After electrophoresis, 
the gel was soaked in fix solution for 30 min and rinsed with three changes of dHzO each 
of 5 min. The gel was then soaked in sensitizing solution for 30 min, and then washed with 
three changes of dHiO each of 10 min, followed by silver reaction for 20 min. The gel was 
developed by shaking in developing solution until the signal was detected. The reaction 
was stopped by shaking the gel in stop solution for 10 min and then in dHzO. 
2.2.2.5 Computer analysis of 2D patterns 
The 2D gels were scanned using Image Scanner (GE Biosciences) and analyzed using 
PDQuest software version 7.3 (Bio-RAD). 
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2.2.2.6 In-gel trypsin digestion 
Destaining gel for in-gel digestion 
Protein spots of interest were cut out from 2D gels with surgical needles and put into 
1.5 ml tubes. For more efficient digestion, the protein spots were first cut into smaller 
pieces with surgical needles. For Coomassie Blue staining, the gels were destained with 
SOO^ il of destaining solution (50% MeOH/50mM NH4HCO3) for 10 min with occasional 
mixing. This step was repeated twice until the spots were totally destained. For silver 
staining, the gels were destained with 20 [i\ of 30 mM potassium ferricyanide:100 mM 
sodium thiosulphate (1:1) solution. Once the dark stain was removed, the gels were washed 
with distilled water and equilibrated with 200 mM NH4HCO3 for 10 min. The step was 
repeated for 3 times. 
In-gel trypsin digestion 
After destaining, the gels were dehydrated with 100 |il of acetonitrile (ACN) for 3 min 
with occasional mixing. This step was repeated twice until the dehydrated gels became 
white in color. Then the gels were dried by SpeedVac (Savant) for about 2 min, rehydrated 
with 10|il trypsin enzyme solution (40 ng/}il trypsin in 50 mM NH4HCO3), and incubated 
on ice for 30 min. After the incubation, 5 \x\ of 50 mM NH4HCO3 solution was added to 
cover the hydrated gel piece. The trypsin digestion was performed by incubating the 
samples at 37°C overnight. On the next day, extraction of digested peptides was performed. 
First, 20 }il of 50 mM NH4HCO3 was added to the gels which were then subjected to 
sonication for 10 min. After that, 20|il of acetonitrile (ACN): 5% triflouroacetic acid (TFA) 
(1:1) solution was added into the 1.5 ml tubes and the samples were sonicated for another 
10 min. The supernatant containing the extracted peptide was then transferred to a new 
tube. This step was repeated twice and supematants were combined. Finally, the gels were 
32 
dehydrated by adding 10 [d of ACN and sonicated for 10 min. The supernatant extracts 
were again removed and combined to the above supernatant extracts. The total supernatant 
extracts (about 90 |il) were dried in SpeedVac for around 3 hr. The dried pellet of digested 
peptides were kept at -20 °C for up to one week or used for mass spectrometric analysis 
directly. 
Resuspension and desalting of the digested peptides 
The vacuum-dried samples were resuspended in 10 |il of 0.1% TFA. The ziptip-C18 
(Millipore) was used to concentrate, desalt and purify the digested peptides. The ziptip was 
first washed with 10 i^l of wetting solution (50% ACN). This step was repeated once. Then 
the ziptip was equilibrated with 10 |il of 0.1 % TFA. This step was also repeated once. The 
digested peptides were then loaded into ziptip by pipetting up and down for 10 cycles. The 
ziptip was then washed 5 times with 0.1% TFA. The peptides were then eluted with 2 jiil of 
elution solution (50 % ACN/0.1% TFA) in a clean 0.5 ml tube by pipetting the peptide 
samples up and down for 5 times. Then, 0.5 |il of the eluted sample was spotted onto each 
spot of a cleaned 192-well MALDI plate (Applied biosystems). When the sample spots 
were dried, 0.5 \i\ of matrix solution (5 mg/ml of ACH-Cinnamic acid in elution solution) 
was added on top of the sample spots. Then the plate was ready for mass spectrometry 
analysis. 
2.2.2.7 Mass spectrometric analysis 
Mass spectrometry was performed with 4700 Proteomics Analyzer (Applied 
Biosystems). The MS or MS/MS results were searched against the NCBI Drosophila 
peptide database and analyzed using GPS Explorer TM Software-Results Browser Version 
2.0 (Applied Biosystems). 
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2.2.3 Detection of NIs by flow cytometry 
Besides the approaches described above, other alternative approaches were also 
performed to study NI proteins. Flow cytometry has been reported to detect and isolate NIs 
from cultured cells (Hazeki et al., 2002; Mitsui et a l , 2002). This approach may allow the 
isolation of NIs in large amount routinely. 
Sixty fly heads overexpressing the unexpanded MJDtrQ27 protein and the expanded 
MJD protein were homogenized in IX PBS buffer (section 2.9). Cell debris was removed 
by low-speed centrifugation at 5,000 rpm at 4°C for 15 minutes. NIs were immunostained 
by anti-HA antibodies recognizing the MJD proteins fused with HA tag. The supernatant 
was incubated with the rabbit anti-HA primary antibody (Zymed) (1:300) at 4°C overnight, 
and the FITC conjugated anti-rabbit secondary antibodies (1:300) at room temperature for 
2 hr. The supernatant containing the NIs was subjected to flow cytometric analysis 
(FACSort，Becton Dickinson) and sorted at a flow rate of 500 particles per min using a 100 
|im outlet nozzle as defined previously (Hazeki et al., 2002; Mitsui et al., 2002). Since the 
average size of NIs had previously been determined to be around 5 [xm (Mitsui et al, 2002), 
particles detected with fluorescent signals and size around or bigger than 5 [xm were 
regarded as NIs. Control was performed using flies overexpressing the unexpanded 
MJDtrQ27 protein according to the same procedures described above. 
2.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
2.3.1 Sample preparation for SDS-PAGE 
Fly heads with suitable phenotype were cut and homogenized in 6X protein sample 
buffer (section 2.9) using a plastic pestle fitted into motorized plastic pestle (Kontes). The 
sample were then boiled at 99 °C for 2 min and stored at -20 °C until use. 
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2.3.2 SDS-PAGE 
All SDS-polyacrylamide gels were run using the Mini-PROTEAN III electrophoresis 
cell (BioRad). The glass plate were cleaned and assembled according to manufacturer's 
instructions. The resolving gel solution was prepared (section 2.9) and transferred into the 
gap between the glass plates, isopropanol was then added onto the top of the gel to keep 
the gel solution out of atmospheric oxygen and to remove bubbles. Then the stacking gel 
solution was also prepared (section 2.9). After the resolving gel solution polymerized 
completely in about 15 min, the isopropanol was poured off and the gel surface was 
washed with water and dried. The stacking gel solution was then transferred onto the top of 
the resolving gel and a comb of 0.75 mm or 1.5 mm thickness with 10 or 15 wells was 
inserted between the glass plates. After the stacking gel set, the comb was removed and the 
wells were washed with dHiO. The gel cassette was then assembled into the 
electrophoresis cell. The inner chamber was filled with fresh SDS-electrophoresis buffer 
(section 2.9) and the outer chamber with fresh or reused buffer. Appropriate volume of 
protein samples were loaded into the wells. Before loading, the samples were denatured by 
heating in a thermomixer at 99 °C for 2 min. 
Electrophoresis was performed at constant voltage of 80 V and changed to 120 V after 
the dye front passed the stacking gel. Electrophoresis was performed until the dye front 
reached the bottom of the running gel. The gel was then removed from the electrophoresis 
cell and stained with Coomassie Brilliant blue R250 or silver stain (section 2.2.2.4), or 




After electrophoresis, the gel was equilibrated in transfer buffer for a few min. PVDF 
membranes (PALL) and 6 pieces of Whatman 3-mm filter paper with similar size of the 
gel were prepared. The PVDF membrane was first soaked in analytical grade methanol and 
then equilibrated in transfer buffer (section 2.9) for a few min. The 3 mm filter papers and 
the fiber pads were also soaked in transfer buffer. 
Electroblotting was carried out by Mini Trans-Blot electrophoretic transfer cell (Bio-
RAD). One wetted white fiber pad was placed onto the cathode of the gel holder cassette 
(black side of the cassette), followed by a stack of 3 wetted filter papers. Then, the gel was 
placed on top of the filter papers, followed by the PVDF membrane, a stack of 3 wetted 
filter papers and 1 fiber pad in order. The sandwich was rolled over using a glass tube to 
expel the air bubbles. The cassette was then assembled and placed into the tank, together 
with the frozen Bio-Ice cooling unit. The tank was then filled with IX transfer buffer and 
Western Blotting was performed at constant voltage of 80 V for 2 hr. 
2.4.2 Western blotting 
Electroblotted membrane was first washed in TBS buffer for 5 min twice, and then 
blocked by 5 % (w/v) non-fat milk in TEST buffer (section 2.9) for 1 hour at room 
temperature with continuous shaking. The membrane was then blotted with primary 
antibodies in 5 % (w/v) non-fat milk of TEST buffer and incubated overnight at 4 °C with 
continuous rolling. The primary antibody can be saved and reused for several times. The 
membrane was then washed with 4 changes of TEST each of 15 min. The membrane was 
then blotted with secondary antibodies conjugated with horseredish peroxidase (HRP) 
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(Zymed) in 5 % (w/v) non-fat milk of TEST buffer at room temperature for 1 to 2 hr with 
continuous rolling, followed by washing with 4 changes of TEST each of 15 min. 
For HRP-conjugated secondary antibody, ECL Western Blotting detection reagents 
(Amersham) was used. 0.5 ml of solution A and 0.5 ml of solution B were mixed. The 
PVDF membrane was then applied to the mixed solutions at room temperature for 1 min. 
The membrane was then wrapped with a plastic wrap and exposed to Kodak BioMax MR 
film at specific time intervals. After that, the film was developed using X-Ray film 
processor (M35X-MOT processor, Kodak). 
2.4.3 Filter trap assay 
Filter trap assay was performed to detect the presence of NI protein complex in the 
samples. Since the diameter of NIs are previously found to be around 5 |im (Mitsui et al., 
2002), any NIs in the samples should be trapped by the cellulose acetate filter membrane 
with the pore size of 0.2 \xm while other proteins with a diameter smaller than 0.2 |Lim 
would be driven away by vacuum. 
Fly heads overexpressing the expanded MJDQtr61 or MJDtrQ78s proteins were cut 
and homogenized in 2 % SDS with 50 mM DTT. Extract without head debris was 
subjected to ultra-centrifugation for fractionation at 100,000 rpm at 4°C for 60 min. Pellets 
containing the NIs and other large cellular proteins were resuspended with 2% SDS with 
50 mM DTT, 40% FA, 60% FA or 100% FA. The samples were subjected to serial dilution 
and then boiled at 99°C for 2 min. 
For the filter trap assay, the cellulose acetate filter membrane with pore size of 0.2 
j^ m (Sartorius) was assembled into the Slot Blot Manifold blot (Amersham Pharmacia 
Biotech PR 648). The blot was then connected to vacuum pump. 200 |al of distilled water 
was first pipetted onto each slot of the blot to equilibrate the membrane. When the solution 
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was driven away by the vacuum, the samples were then pipetted onto the blot followed by 
two wash of distilled water. The membrane was then taken off the blot and washed with 
IX PBST for 5 min and then blocked with 5 % milk in PBST for 1 hr. Then the membrane 
was blotted with primary antibodies at 4°C overnight and washed with IX PBST for four 
times of 15 min, followed by HRP-conjugated secondary antibodies at room temperature 
for 1 hr and washed with IX PBST for four times of 15 min. The membrane was then 
ready for detection using ECL reagents following the procedures as described in section 
2.4.2. 
2.5 Sav antibody production 
2.5.1 Sav peptide synthesis 
A short peptide sequence of Sav (Flybase CG13831) was chosen for peptide synthesis. 
The chosen sequence was CVGKYMKKDTPPDISV-NH2 of 16 amino acids based on high 
antigenicity. The peptide was synthesized by Peptron Inc (www.peptron.com) with N-
terminal KLH conjugation, C-terminal amidation and greater than 90 % HPLC purification. 
2.5.2 Rabbit immunization 
Mixing antigen and adjuvant 
The antigen was suspended in PBS solution to 100 |Lig protein/ml. The synthetic 
peptide was mixed with conjugant using glass syringe size fitted with a gauge needle. The 
ratio of antigen and adjuvant was 1:1. Emulsification was achieved by using two sterile 
Luer-lok syringes connected through a sterile three way tap. The adjuvant/immunogen 
solution was then forced through repeatedly between the two syringes. Mixing was 
continued until the emulsion become milky and then pasty. 
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Priming rabbits 
About 30 ml of blood was removed as the baseline pre-immune serum before first 
immunization. For priming the rabbits, the mixed antigen-adjuvant emulsion was injected 
into the two female rabbits (origin of New Zealand) subcutaneously. The region to be 
injected was shaved and the injected sites were swabbed with 70% alcohol. About 1 ml of 
the emulsion was injected per rabbit, and a new gauge sterile needle was used for each 
injection. Each site was massaged gently following injection. 
Boosting and bleeding rabbits 
The first boost was performed by administering 1 ml of antigen-adjuvant emulsion to 
the rabbits 4-6 weeks following the initial dose. A bleeding of 30 ml was taken 7 to 10 
days later. In the same way, a further three doses and bleeds were undertaken with the 
intervals of 4-6 weeks apart. 
2.6 Cryosectioning and immunostaining of adult fly heads 
Fly heads were cut and submerged in O.C.T. embedding solution (Sakura). A 0.5 cm 
diameter O.C.T. blob was made by squeezing the O.C.T. solution onto the lid of a petri-
dish and then freezed at -70°C for a few min. The blob was then placed onto a petri-dish 
containing dry ice. Just before embedding the fly heads, a small drop of O.C.T. solution 
was squeezed on the large blob which served as the platform. When the O.C.T. solution 
was still in liquid state, fly heads were placed onto the small drop of the O.C.T. solution 
with the upright orientation (the head faced upward and the eyes faced forward) and the 
orientation was marked. After the O.C.T. solution was solidified, the whole blob was 
submerged into liquid nitrogen for a few seconds. The detached small blobs with fly heads 
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embedded inside were then placed into a Falcon and stored at -20°C until cryostat 
sectioning. 
The embedded heads were sectioned using cryostat machine (HM505E, Microm). The 
thickness of the sectioning was adjusted to 12 i^m. After sectioning, the section was 
adhered to a slide pre-coated with 1% gelatin solution to increase adhesion of sections on 
the slides. The sections on the slide were fixed immediately by submerging in 0.5% 
formaldehyde solution for 30 min, and then washed in three changes of IXPBS solution 
each of 10 min. The sections were then blocked in PBSG solution for 60 min. After 
removing the blocking solution entirely, the section was incubated with primary antibodies 
at 4 � C overnight. On the second day, the sections were washed with three changes of 
IXPBS solution each of 10 min, then incubated with secondary antibodies (Zymed FITC 
goat anti-rabbit secondary antibodies 1:150 or/and Zymed cy3 goat anti-mouse secondary 
antibodies 1:150) diluted in PBSG at room temperature for 2 hr. After that, the sections 
were further incubated with DAPI nucleic acid stain (Molecular Probes) at a dilution of 
1:75 for 2 min and washed with three washes of IXPBS solution each of 10 min. For 
mounting the slide, about 100 i^l of the antifade solution (ProLong Antifade Kit, Molecular 
Probes) was first applied to the slide and covered with the cover slips. The edges of the 
cover slips were sealed using nail oil. After mounting the slide, images and fluorescent 
signals were captured by CCD camera and processed by the image software of Spot 
Advanced Version 3.5.9 (Diagnostic Instrument Inc.). 
2.7 Alcohol dehydrogenase assay 
Fifty fly heads expressing the MJDtrQ27, MJDtrQ61 or MJDtrQ78s proteins were 
cut and homogenized in 120 pi of 10 mM potassium phosphate buffer pH 7.0 (section 2.9). 
Extract was subjected to alcohol dehydrogenase assay. The reaction mixture was consisted 
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of 500 |il distilled water, 250 of IM tris-HCl pH8.8, 100 absolute ethanol, 100 of 4 
mM NAD+ and 50 [d of fly protein extract. The mixture was mixed and the absorbance 
was measured in a glass cuvette at 340 run. The alcohol dehydrogenase activity was 
measured as the rate of formation of NADH indicated by the absorbance at 340nm. The 
change of absorbance was measured and recorded for a 120 s interval using the 
spectrophotometer (Ultrospec 3000, Pharmacia Biotech). 
2.8 Semi-quantitative Reverse Transcription-Polymerase Chain 
Reaction 
2.8.1 Total RNA preparation from fly heads 
Total RNA was extracted from adult fly heads using Trizol reagent (Invitrogen) 
according to the manufacturer's instructions. In brief, 16 adult fly heads were homogenized 
in 800 fil of Trizol reagent with a plastic pestle. 160 |il of chloroform was then added. 
Samples were centrifuged at 4 °C for 15 min. The aqueous upper phase was transferred to 
a new tube and 400 fil of isopropanol was added to precipitate the RNA. The RNA was 
then washed with 70 % ethanol and dissolved in 50 fil of diethyl pyrocarbonate (DEPC)-
treated water. 
2.8.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
For reverse transcription, 4 \i\ of total RNA was mixed with 1 fil of oligo (dT) primer 
(10 |iM, Roche). The mixture were heated at 70 °C for 5 min and then chilled on ice for 5 
min. For complementary DNA (cDNA) synthesis, the reaction mixture contained the 
following components: 4 \x\ of 5X reaction buffer (Promega), 0.5 i^l of 20 mM 
deoxynucleoside triphosphates (dNTPs) mixture (GE Biosciences), 0.5 \x\ of recombinant 
ribonuclease inhibitor (40 U/[il, Invitrogen), 2.4 [xl of 25 mM of magnesium chloride 
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(Promega) and 1 jil of reverse transcriptase (Promega). The reaction was performed at 42 
°C for 1 hr and stopped by heating the reaction mixture at 70 °C for 15 min. PGR 
amplification was then performed and actin was used as the internal control. For RACKl, 
the PGR cycles were as follow: 95�C for 6 min; 30 cycles of 95 °C for 30 s, 5 8 � C for 30 s, 
and 7 5 � C for 30 s. RACKl forward primer sequence was 5，CTA CGA CAC TCG CAC 
TTC A 3, and the reverse primer sequence was 5'AGG TTC TTG CCG TCA TTG AGS'. 
For actin, the PGR cycles were 95 for 6 min; 25 cycles of 9 5 � C for 30 s, 60 °C for 30 s, 
and 75 °C for 30 s. Actin forward primer sequence was: 5' ATG TGC AAG GCC GGT 
TTC GC 3' and reverse primer sequence was 5, CGA CAC GCA GCT CAT TGT AG 3，. 
Both RT and PGR were run on i-Cycler (Bio-RAD). 
2.9 Reagents and buffers 
Reagents for two-dimensional gel electrophoresis 
2D rehydration buffer 
8 M urea 
2 % CHAPS, 
0.002 % bromophenol blue 
Lysis buffer 
8 M urea, 
4 % CHAPS 
60 mM DTT 
2% Pharmalyte 3-10 
0.002 % bromophenol blue 
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Resolving gel solution (12 % polyacrylamide) for one 1 mm large gel of 16cmx20cm 
30 % acrylamide 15.75 ml 
1 M Tris-HCl pH 8.8 1 4.65 ml 
dHiO 8.55 ml 
10%SDS 3941^1 
10% ammonium persulfate 157.5 |li1 
TEMED 18 III 
Equilibration buffer 
Urea 6 M 
Tris-HCl, pH8.8 50 mM 
SDS 2 % 
Glycerol 30 % 
Bromophenol blue 0.002 % 
Equilibration buffer containing dithiothreitol (DTT) 
100 mg DTT in 10 ml equilibration buffer 
Equilibration buffer containing iodoacetamid (lAA) 
100 mg lAA in 10 ml equilibration buffer 
Agarose sealing solution 
agarose (0.5 %) 0.5 g 
bromophenol blue (0.002 % w/v) 200 
In 100 ml SDS electrophoresis buffer 
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Reagents for Protein Staining 
Coommassie Brilliant Blue Staining solution 
Coommassie Brilliant Blue R250 (0.25 % w/v) 2.5 g 
Methanol 45 % 450 ml 
Acetic acid 10% 00 ml 
Made up to IL with deionized water 
Destaining solution for Coommassie Brilliant Blue 
Methanol 45 % 
Acetic acid 10 % 
Made up to 1 L with deionized water 
Reagents for SDS electrophoresis 
Protein Sample Buffer (6X) 
Tris Base (100 mM) 5 ml IM Tris/HCl, pH6.8 
SDS (2 %) 10 ml 10% SDS ‘ 
Glycerol (20 %, w/v) 10 ml Glycerol 
P-mercaptoethanol (5 %) 2.5 ml 
Bromophenol blue (0.02 %) 0.01 g 
Made up to 50 ml with deionized water. 
SDS electrophoresis buffer (lOX) 
Tris Base (0.25 M) 30.28 g 
Glycine (1.92 M) 144.13 g 
SDS (1 %) 10 g 
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Made up to 1 L with deionized water, adjusted to pH 8.3, diluted to IX before use. 
Resolving gel solution of (12 % polyacrylamide) for two 0.75 mm mini gels 
30 % aery 1 amide 3.5 ml 
1 MTris-HCl pH 8.8 3.255 ml 
啦 0 1.9 ml 
10% SDS 87.5 1^1 
10% ammonium persulfate 35 
T E M E D 4 
Stacking gel solution of (4.2% polyacrylamide) for two 0.75 mm mini gels 
30% acrylamide 0.49 ml 
1 MTris-HCl pH 6.8 0.966 ml 
dHiO 1.96 ml 
1 0 % SDS 35 1^1 
10 % ammonium persulfate 14 |li1 
T E M E D 4 III 
Reagents for Western blotting 
Transfer buffer (lOX) 
Tris Base (0.25 M ) 30.28 g 
Glycine (1.92 M ) 144.13 g 
Made up to IL with deionized water, diluted to IX with 100 ml methanol and 800 ml 
deionized water before use. 
45 
Tris-buffered saline (TBS) (lOX) 
Tris Base (0.2 M ) 24.22 g 
NaCl(1.37M) 80.06 g 
Made up to IL with deionized water, adjusted to p H 7.6 with 6 M HCl, diluted to IX before 
use. 
Tris-buffered saline- Tween 20 (TEST) 
Tween 20 (0.05 % ) 0.5 ml 
In IL IX T E S T 
Blocking buffer (5% non-fat milk) 
Non-fat milk powder (5 % ) 5 g 
In 100 ml I X T B S T 
Reagents for immunostaining 
Phosphate Buffered Saline (PBS) (lOX) 
NaCl (137 m M ) 80.06 g 
KCl (2.7 m M ) 2 g 
Na2HP04-7H20 (10 m M ) 26.8 g 
KH2PO4 (2 m M ) 2.4 g 
Made up to IL with deionized water, adjust to pH 7.4 with 6 M HCl, diluted to IX before 
use. 
PBSG 
Goat serum (1.0%) 0.5 ml 
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B S A (0.2 o/o) 1 ml of 10% B S A 
Saponin (0.01 % ) 50 of 10% saponin 
Made up to 50 ml with IX PBS 
Reagents for nucleic acid electrophoresis 
TBE (Tris-borate-EDTA) (5X) 
Tris base 54 g 
Boric acid 27.5 g 
E D T A 20 ml ofO.5 M E D T A , pH 8.0 
Diluted to 0.5X before use. 
6x agarose gel loading buffer 
Bromophenol blue 0.25 % (w/v) 
Sucrose 40 % (w/v) 
E D T A (pH 8.0) 60 m M 
Antibodies 
Cy3 goat anti-mouse secondary antibodies, Zymed 
FITC goat anti-rabbit, Zymed 
Mouse anti-E7, Developmental Studies Hybridoma Bank, University of Iowa, U S A 
Mouse anti-GFP (JL8; B D Biosciences) 
Mouse anti-RACKl, B D Biosciences Pharmingen 
Rabbit anti-androgen receptor，N20, Santa Cruz Biotech 
Rabbit anti-HA, Zymed, 
Rabbit anti-Hsp70, SPA812, Stressgen 
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3. RESULTS 
3.1 Transgenic polyglutamine fly models 
Several polyglutamine fly models were used in this study including the Machado-
Joseph Disease (MJD)/spinocerebellar ataxias 3 (SCA3) model (Warrick et al., 1998), the 
spinal and bulbar muscular atrophy (SBMA) model (Takeyama et al., 2002) and the 
spinocerebellar ataxia 1 (SCAl) model (Femandez-Funez et al., 2000). The main model 
used for most of the experiments was the M J D model, which was also the first 
polyglutamine fly model being generated (Warrick et al., 1998). SCAl model expresses 
the full-length human polyglutamine proteins, whereas M J D and S B M A models express 
the truncated human polyglutamine proteins. The use of different models may give further 
confirmation of results as well as insight into disease specific pathways. Below, 
characterization of the M J D model showed that polyglutamine fly models are legitimate 
for studying polyglutamine diseases. 
3.1.1 Characteristics of MJD polyglutamine fly model 
The M J D fly model was generated by overexpressing the truncated human M J D 
proteins in flies (Warrick et al., 1998). The pathogenic M J D models used in this study are 
flies overexpressing the truncated expanded M J D proteins of 61 glutamine repeats 
(MJDtrQ61) and 78 glutamine repeats strongly (MJDtrQ78s). Whereas the non-
pathogenic M J D model is flies overexpressing the truncated unexpanded M J D protein of 
27 glutamine repeats (MJDtrQ27). The detailed characteristics of these models are 
described below. 
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3.1.1.1 Overexpression of expanded truncated human MJD proteins in 
Drosophila causes eye degeneration 
The truncated human M J D proteins were overexpressed in Drosophila eyes using 
gmr-GAL4/UAS expression system (Brand and Perrimon, 1993). Fly overexpressing the 
MJDtrQ27 protein (Fig. 7B) in eyes showed red eye pigment and regular ommatidial 
structures as the control transgenic fly overexpressing the G A L 4 proteins (Fig. 7A). Fly 
overexpressing the MJDtrQ61 protein at 3-day old showed similar external eye phenotype 
as the control transgenic fly without detectable eye degeneration (Fig. 7C). However, aged 
MJDtrQ61 flies showed progressive eye degeneration (Warrick et al., 1998). Fly 
overexpressing the MJDtrQ78s protein resulted in eye degeneration indicated by loss of 
red eye pigment and disruption of regular ommatidial structures (Fig. 7D), which 
correlated well with the internal disruption of retinal structure and neuronal cell death as 
previously described (Warrick et al., 1998; Chan et al., 2000). Hence, the external eye 
depigmentation phenotype can be used as an indicator to reflect the status of 
neurodegeneration. 
3.1.1.2 Overexpression of expanded truncated human MJD proteins in 
Drosophila results in nuclear inclusion formation 
Formation of NIs is a hallmark of most polyglutamine diseases (Zoghbi and Orr, 
2000). Immunostaining of adult polyglutamine fly heads overexpressing the unexpanded 
MJDtrQ27 protein showed no NIs was formed and the MJDtrQ27 protein displayed a 
diffused cytoplasmic distribution (Fig. 8A). However, flies overexpressing the MJDtrQ61 
(Fig. 8B) and MJDtrQ78s (Fig. 8C) proteins resulted in the formation of NIs and the 
recruitment of the M J D proteins into the NIs, similar to that in polyglutamine disease 
patients (Zoghbi and Orr, 2000). 
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_ _ _ _ 
Figure 7. Overexpression of expanded truncated human Machado-Joseph Disease 
(MJDtr) proteins in Drosophila eyes causes eye degeneration. Fly overexpressing the 
une邓anded MJDtiQ27 protein (B) showed red eye pigment and regular ommatidial 
structure as the control transgenic fly overexpressing the GAL4 protein (A). Fly 
overexpressing the expanded MJDtrQ61 protein at 3-day old showed no apparent 
external degeneration (C). Fly overexpressing the expanded MJDtrQ78s protein caused 
eye degeneration indicated by loss of red eye pigment (D). 
MJDtrQ27 MJDtrQ61 MJDtrQ78s 
Figure 8. Immunostaining of adult fly heads overexpressing the expanded 
truncated human Machado-Joseph Disease (MJDtr) proteins results in formation 
of polyglutamine nuclear inclusions (NIs). Fly overexpressing the unexpanded 
MJDtrQ27 protein showed diffiised distribution of the protein without formation of NIs 
(A). Fly overexpressing the expanded MJDtrQ61 (B) and MJDtrQ78s (C) proteins 
resulted in the formation of polyglutamine protein-positive NIs (white arrows). 
Antibodies used was rabbit anti-HA staining the HA tagged-MJD proteins (Zymed). 
Images were captured using Olympus BX51 microscope and Spot Advanced software 
Version 3.5.9 (Diagnostic Instrument Inc.). The magnification was 40X. 
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3.1.1.3 Formic acid dissolves fly polyglutamine nuclear inclusions 
NIs are large protein complex which are SDS-insoluble and trapped in the SDS-
P A G E stacking gel (Chan et al., 2000). Nevertheless, it was found that F A could dissolve 
NIs in vitro (Hazeki et al., 2000). Here, experiments were performed to investigate the 
ability of F A in dissolving NIs isolated from polyglutamine flies. 
3.1.1.3.1 Formic acid dissolves fly polyglutamine NIs as shown by Western blot 
analysis 
Fly heads overexpressing the MJDtrQ61 and MJDtrQ78s proteins were 
homogenized in protein sample buffer and subjected to Western blot analysis. Majority 
of the expanded M J D proteins were resided in the stacking gel, indicating that the 
proteins were SDS-insoluble (Fig. 9A, lanes 1 and 3). After the treatment with 100% FA, 
the expanded M J D proteins became SDS-soluble and migrated into the separating gel, as 
indicated by the increased intensity of the protein monomeric bands (Fig. 9 A, lanes 2 and 
4). The amount of protein monomer of another NI protein, the heat shock protein 70 
Hsp70 (Bonini, 2002), also increased after the treatment with 100% FA (Fig. 9C). For 
another polyglutamine model, the S B M A model, F A could also increase the amount of 
the expanded androgen receptor protein monomer (Fig. 9B). Therefore, the Western blot 
showed that F A could dissolve NI proteins from the NIs. 
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Figure 9. Formic acid (FA) solubilizes polyglntamine nuclear inclusion (NI) 
proteins. The Western blot showed that majority of the expanded polyglutamine 
proteins overexpressed in flies, the expanded truncated MJDtr proteins {MJDtrQ78s in 
lane 1 of A and MJDtrQ61 in lane 3 of A) and the expanded androgen receptor protein 
(ARtrQ112w in lane 1 of B and ARtrQ112s in lane 3 of B) were SDS-insoluble and 
resided in the stacking gel (red bar). Only residual amount of the disease proteins were 
SDS-soluble (arrows). However, FA treatment solubilized the expanded polyglutamine 
proteins from NIs as indicated by the disappearance of the stacking gel protein complex 
(red bar) and the increase of SDS-soluble (arrows) protein monomers (lanes 2, 4 of A 
and B). Hsp70, a commonly found NI protein, was also recruited to SDS-insoluble NIs 
(red bar) in MJDtrQ78s fly (lane 1 of C). Upon FA treatment, soluble amount of Hsp70 
also increased (lane 2 of C). Antibodies used were rabbit anti-HA staining the HA 
tagged-MJD proteins (Zymed), rabbit anti-androgen receptor (B, N20, Santa Cruz 
Biotech) and rabbit anti-Hsp70 (C, SPAS 12, Stressgen). w (weak-expressing) and s 
(strong-expressing) represent the different expression levels of the disease proteins. 
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3.1.1.3.2 Formic acid dissolves fly polyglutamine NIs as shown by filter trap 
assay 
Besides Western blot analysis, the ability of F A to dissolve fly NIs was also 
investigated by filter trap assay (Wanker et al., 1999). The principle of this assay is that 
any protein larger than the pores of the filter membrane would be trapped on the 
membrane and be detected. Previous study found that the diameter of NIs is about 5 )im 
(Mitsui et al., 2002). Since the diameter of filter membrane pore is 0.2 the NIs 
would be trapped on the filter membrane, if any. Proteins extracted from the MJDtrQ61 
flies and the MJDtrQ78s flies were treated with different concentrations of FA. 
Results of the filter trap assay showed that both MJDtrQ61 and MJDtrQ78s proteins 
were trapped on the membrane when treated with low concentration of F A (40% FA) 
(Fig. lOA and D). However, the amount of the expanded M J D proteins trapped on the 
membrane decreased when the samples were treated with increasing concentration of FA 
(60% FA in Fig. lOB and E; 100% F A in Fig. IOC and F). Since the diameters of M J D 
proteins are smaller than 0.2 jim, it is speculated that the whole complex of NIs with the 
recruited M J D proteins were trapped on the membrane. The filter trap assay showed that 
the expanded M J D proteins could be extracted from the NIs by FA, and the extracting 
power increased with increasing concentration of FA. However, the signal for the 40% 
FA treated sample seemed to be less than that treated with 60% F A in MJDtrQ61 (Fig. 
lOA-C). It may be due to the variation of individual sample quantification. 
To conclude, both Western blot analysis and filter trap assay showed that FA could 
dissolve NIs isolated from polyglutamine flies. Therefore, F A can be used to dissolve 
NIs prior to electrophoretic separation and identification of the individual NI proteins. 
53 
MJDtrQ61 






1 2 3 4 5 6 




Figure 10. Formic acid (FA) solubilizes polyglutamine nuclear inclusion (NI) 
proteins shown by filter trap assay. Proteins were extracted from MJDtrQ61 and 
MJDtrQ78s flies using protein sample buffer and then treated with FA. The FA-
treated samples were diluted serially and filtered through cellulose acetate membrane 
with pore size of 0.2 陣 .B o t h MJDtrQ61 (A) and MJDtrQ78s (D) proteins were 
trapped on the membrane when treated with 40% FA. When treated with higher 
concentration of FA (60% FA), the amount of membrane-trapped expanded MJD 
proteins decreased (B and E). Almost no MJDtr disease proteins were detected when 
treated with 100% FA (C and F), indicating the NI proteins being solubilized by FA. 
Lanes 1-6 representing six subsequent serial dilutions from 10"^  tolO"^ . Antibodies 
used was rabbit anti-HA staining the HA tagged-MJD proteins (Zymed). 
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3.1.2 Summary 
To sum up, M J D fly models exhibited characteristic features of polyglutamine 
diseases as in human patients, including neurodegeneration and formation of NIs. 
Besides, NIs prepared from polyglutamine flies can be dissolved by FA. Therefore, the 
polyglutamine fly models are legitimate for subsequent study of polyglutamine NI 
proteins. 
Besides, it was suggested that the MJDtrQ61 model was less pathogenic than the 
MJDtrQ78s model with less cell death. Hence, more proteins could be extracted from the 
MJDtrQ61 model for experiments such as 2D gel electrophoresis. In view of this, the 
MJDtrQ61 model was used in most experiments instead of the MJDtrQ78s model. 
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3.2 Proteomic identification of nuclear inclusion (NI) proteins 
Studies of polyglutamine diseases have been carried out intensively over the past 15 
years (La Spada et al., 1991). Different approaches such as microarray analysis (Chan et al., 
2002a; Luthi-Carter et al., 2002; Sipione et al., 2002) and genetic modifier screens 
(Kazemi-Esfarjani and Benzer, 2000; Faber et al., 2002; Kazemi-Esfarjani and Benzer, 
2002) have been used to identify polyglutamine pathogenic pathways. 
In this study, I used a new approach to study polyglutamine pathogenic pathways by 
identifying polyglutamine NI proteins. According to the protein depletion theory, the 
recruitment of cellular proteins into the NIs would undermine their normal functions and 
contribute to polyglutamine pathogenesis in certain extent. Therefore, identification of NI 
proteins would be a viable approach to discover novel pathogenic pathways and potential 
therapeutic interventions of polyglutamine diseases. 
To date, a thorough investigation of polyglutamine NI proteins is still lacking. 
Previous studies of NI proteins were mainly based on in vitro cell models and only a short 
list of NI proteins had been found (Suhr et al., 2001; Mitsui et al., 2002; Doi et al, 2004). 
It is suggested that the list is not yet saturated since different groups found different subsets 
of NI proteins. In view of this, the present project aimed to identify a more complete list of 
NI proteins, which may contribute to a more comprehensive understanding of 
polyglutamine pathogenic mechanisms. 
3.2.1 Proteomic identification of NI proteins by SDS-insolubility of 
NIs 
As an initial attempt, I made use of the SDS-insoluble properties of NIs for 
identification of NI proteins. It was shown above that NIs are SDS-insoluble and resided in 
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the SDS-PAGE stacking gel (Fig. 9A, lane 1 and 3). Hence, it should be feasible to identify 
NI proteins by cutting out the stacking gel for in-gel digestion and mass spectrometric 
identification. This method was named as the "stacking gel approach". 
Proteins were extracted from the MJDtrQ27 and MJDtrQ61 flies by protein sample 
buffer and then subjected to SDS-PAGE. For the control MJDtrQ27 sample, no NI 
complex was detected in the stacking gel. For the MJDtrQ61 sample, NIs were formed and 
resided in the stacking gel. The stacking gels were cut out for both MJDtrQ27 and 
MJDtrQ61 samples and subjected to trypsin in-gel digestion and then mass spectrometric 
analysis. Those proteins found from the MJDtrQ61 sample but not from the MJDtrQ27 
sample would correspond to the potential NI protein candidates according to the above 
rationale. 
The mass spectrometric results were analyzed by the GPS explorer T M software and 
searched against the NCBI database. All the proteins were identified by the software with 
the confidence set to be 95% matched. From the mass spectrometric results, 38 protein 
candidates were identified from the MJDtrQ61 sample, while only 2 proteins were 
identified from the control MJDtrQ27 sample (Table 3), which might be contaminants. 
Since all the 38 protein candidates found from the MJDtrQ61 sample were not identified in 
the control sample, they were regarded as potential NI protein candidates. 
From the candidate list, the majority were newly identified NI proteins involved in 
diverse cellular processes such as transcription, translation, R N A binding, R N A processing, 
protein folding and ubiquitination (Table 3). Among the candidates, four have been 
previously found to colocalize with NIs. They are the small heat shock protein crystalline 
(Dabir et al, 2004), the ubiquitin-specific protease Ulpl (Hazeki et al., 2002), the 
cytoskeleton component actin (Suhr et al., 2001) and the glycolytic enzyme 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Burke et al, 1996; Koshy et al., 
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1996). These previously identified NI proteins serve as positive indicators showing that the 
“stacking gel approach" is feasible for identification of NI proteins. 
Although this approach serves as a convenient and quick way for identification of 
NI proteins, the whole NI complex was subjected to mass spectrometric analysis without 
any well-defined separation of individual NI protein. Therefore, it would reduce the 
accuracy of subsequent mass spectrometric detection. In view of this, a more precise and 
systematic method was performed to identify NI proteins by first separating individual NI 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.2 Proteomic identification of NI proteins by FA-solubility of NIs 
As it has been proved that F A was able to dissolve fly polyglutamine NIs (section 
3.1.1.3), individual NI protein was first extracted from the SDS-insoluble NIs by treating 
with F A prior to electrophoretic separation. The FA-treated samples were then subjected to 
ID gel electrophoresis. However, the protein profiles were too complex and the differential 
bands were difficult to observe (Fig. 11). Thus, 2D gel electrophoresis was performed for 
better separation of the proteins. This method was named as the “2D approach". 
3.2.2.1 Two-dimensional gels showing differential protein spots as potential 
NI proteins 
Fly heads overexpressing the MJDtrQ27 or MJDtrQ61 proteins were homogenized, 
subjected to ultracentrifugation for fractionation of the NIs and followed by FA treatment. 
The protein samples were then subjected to 2D gel electrophoresis. For each set of 2D gels, 
three gels were run simultaneously including the MJDtrQ27 sample treated with 100% FA 
(Fig. 12-19, gel A), the MJDtrQ61 sample without F A treatment (Fig. 12-19, gel B) and 
the MJDtrQ61 sample treated with 100% F A (Fig. 12-19, gel C). Totally, five sets of 
Coomassie Blue-stained and three sets of silver-stained 2D gels were run. Since different 
staining methodologies give different detection sensitivity, the use of both stainings would 
allow detection of proteins with a wide range of intensity. 
By comparing gel C (MJDtrQ61 sample treated with 100'% FA) to gel B (MJDtrQ61 
sample without F A treatment), those differential protein spots only present or with higher 
intensity in gel C represent the NI protein candidates being extracted by FA from the NIs, 
resulting in increased intensity of those proteins. While gel A (MJDtrQ27 treated with 
100% FA) served as the control for isolation of any non-NI proteins, and also to account 
for the effect of F A treatment on these proteins. Both the Coomassie Blue-stained and 
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silver-stained 2D gels showed that a number of differential protein spots which were only 
present or with higher intensity in gel C were detected (Fig. 12-19, gels C). These 
differential spots represented the potential NI protein candidates and were cut out for 
trypsin in-gel digestion and mass spectrometric analysis. 
64 
MJDtrQ78s MJDtrQ61 
• ^ > • * . 
Marker 0% 100% 0% 100% FA 









Figure 11. One-dimensional SDS-PAGE for formic acid-treated and untreated 
nuclear inclusion (NI) samples. Proteins were extracted from MJDtrQ61 and 
MJDtrQ78s flies by protein sample buffer and then treated with 100% FA (lanes 2 
and 4) or without FA treatment (lanes 1 and 3). The samples were then subjected to 
one-dimensional SDS-PAGE and followed by Coomassie Blue staining. The 
protein profile was complex and differential bands were difficult to observe 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.2.2 NI protein candidates identified by the 2D approach 
The mass spectrometric results were analyzed by the GPS explorer T M software and 
searched against the NCBI database. All the proteins were identified by the software with 
the confidence set to be 95% matched. The mass spectrometric results of individual 2D 
runs were summarized in table 4, with the detailed information of each protein candidate. 
Totally, 44 NI proteins were identified by the "2D approach". Among the candidates, 16 
proteins were identified more than once (Table 5). G A P D H , vitellogenin II precursor and 
vitellogenin III precursor were the candidates identified with the highest frequencies 
(Table 5)，reflecting that they were the most probable NI protein candidates. From the list 
of the 44 NI protein candidates, 1 of them had P.I. values below 6, and 33 of them above 8. 
Nevertheless, most of the proteins had their P.I. value around 7. For some of the previously 
identified NI proteins, their P.I. values were also found to have normal distribution from 4 
to 9 (Table 6). Therefore, the findings from the present study agreed with the previous 
studies that most of the NI proteins have the normal distribution of P.I. values. 
From the list, three candidates had previously been found to colocalize with NIs. 
These include the small heat shock protein Hsp27 (Wyttenbach et al.，2002), the ribosomal 
protein RpLPO (Hazeki et al., 2002), and the glycolytic enzyme G A P D H (Burke et al., 
1996; Koshy et al, 1996). Indeed, G A P D H was also found as a NI protein by the “stacking 
gel approach" (Table 3). Hence, these previously identified NI proteins serve as good 
indicators showing that the “2D approach" is feasible for identification of NI proteins. 
Among the candidates, the majority was newly identified NI proteins with diverse 
cellular functions such as metabolic enzymes, kinases, phosphatases, signaling molecules 
and proteasome components (Table 5). They are involved in a wide range of cellular 
processes including apoptosis, energy metabolism, signaling pathway, cell-cell interaction 
and axon targeting (Table 5). According to the protein depletion theory, the recruitment of 
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such a wide range of cellular proteins into the NIs would result in impairment of multiple 
cellular processes and eventually contribute to polyglutamine pathogenesis. Indeed, some 
of these cellular processes have been previously implicated in polyglutamine pathogenesis 
such as apoptotic pathways (Lipinski and Yuan, 2004) and energy metabolism (Brouillet et 
al., 1995; Koshy et al, 1996). 
Compared to the "stacking gel" approach, the "2D approach" is more systematic 
for identification of NI proteins since individual NI protein was first extracted from the NIs 
and separated by 2D gel electrophoresis prior to mass spectrometric identification. 
However, the “2D approach" requires a significant differential protein pattern for 
identification of NI proteins. Therefore, some potential NI proteins would be overlooked if 
their differential patterns are too subtle. 
To conclude, the two approaches used for identification of NI proteins bear their 
own advantages and drawbacks, and hence they could complement each other to give a 
more complete list of NI proteins. However, some false positive NI protein candidates may 
also be identified by both approaches. Therefore, the identified NI protein candidates need 
to be further confirmed in the NIs by other analysis such as immunostaining (sections 
3.3.1.1 and 3.3.2.1.1). 
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Table 6. The isoelectric point (P.L) values of the previously identified NI proteins. 
No. NI proteins P.L values  
1 TATA-binding protein  
2 Myocyte-specific enhancer factor-2a  
3 Ubiquitm 6.94 
4 p53:53 kP 6.48 
5 Grb-2 — 6.1 
6 Huntmgtin  
7 Heat shock protein 84 ^  
• 8 Heat shock protein 70 
9 Caspase-3 — 5.38 “ 
10 Actin ^  
11 Nuclear pore complex protein-Nup62 5.17 
12 Lamm B 5.11 
13 [Light neurofilament protein 4.63 
The P.L values were predicted using the ExPASy programme. 
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3.2.3 Study of polyglutamine NI protein by flow cytometry analysis 
3.2.3.1 Detection of fly polyglutamine NIs by flow cytometry 
Besides the two approaches described above, other approaches can also be used to 
study NI proteins. For example, it has been reported that NIs can be detected and isolated 
from cultured cells by flow cytometry (Hazeki et al., 2002; Mitsui et al, 2002). This 
approach allows large amount of NIs to be isolated routinely. However, it requires 
immunostaining of NIs for flow cytometric detection and isolation. 
To investigate whether NIs from flies can be detected by flow cytometry, fly heads 
overexpressing the MJDtrQ27 and MJDtrQ61 proteins were homogenized in IX PBS 
buffer for flow cytometric analysis. Prior to flow cytometry, NIs was immunostained by 
FITC conjugated antibodies. It has been determined previously that the average diameter 
of NIs was around 5 |Lim (Mitsui et al., 2002). According to the predicted size and the 
fluorescence property of the stained NIs, NIs would reside in quadrant 2 of the sorting 
profile (particles with large size and strong fluorescent signal; Fig. 20). As expected, an 
approximately ten-fold increase of the number of particles were detected in quadrant 2 for 
the MJDtrQ61 sample (Quadrant 2, Fig. 20C) when compared to the MJDtrQ27 control 
sample (Quadrant 2, Fig. 20A). Therefore, the result showed that flow cytometry was able 
to detect NIs isolated from polyglutamine flies. This method can then be adopted for large-
scale isolation of NIs. 
To save the work of doing immunostaining, a new transgenic GFP-polyglutamine 
fly model was generated. The intrinsic fluorescence nature of the GFP-polyglutamine 
proteins would facilitate the detection of the polyglutamine proteins and hence the isolation 
of NIs. Initial characterization of this new model is described below. 
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Figure 20. Flow cytometric detection of polyglutamine nuclear inclusions (NIs). Fly 
heads overexpressing the MJDtrQ27 (A and B) and MJDtrQ61 (C and D) proteins were 
homogenized and immunostained with anti-HA antibody (FITC-labelled). Samples were 
then subjected to flow cytometric analysis. 50,000 particles were counted and assigned 
to four quadrants according to their size and fluorescence intensity. The number of 
particles in each quadrant were counted. According to the fluorescence property of the 
stained NIs and its predicted size (around 5 ^un), NIs would reside in quadrant 2 of the 
sorting profile (particles with large size and strong fluorescent signal). Particle size was 
determined by comparing to the uniform-sized fluorescent beads (not shown). The 
number of particles detected in quadrant 2 for the MJDtrQ6i sample (C and D) were 10 
times more than that detected for the MJDtrQ27 control sample (A and B). The Y-axis 
represents log scale of green fluorescence signal whereas the X-axis represents the size 
of the particles. Antibodies used were rabbit anti-HA staining the HA tagged-MJD 
proteins (Zymed) and goat anti-rabbit FITC conjugate (Zymed). 
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3.2.3.2 Characterization of a new GFP-polyglutamine fly model 
Generation of GFP-polyglutamine transgenic flies 
Constructs of UAS-GFP-polyQ-FLAG (UAS-GFP-Q28-FLAG and UAS-GFP-Q76-
FLAG) were made by Miss Echo Chen (Department of Biochemistry, C U H K ) and 
injected into fly embryos. The GFP moiety allows direct visualization of the 
polyglutamine proteins, whereas the F L A G epitope can be used for immunodetection of 
the fusion protein. It had been previously shown that transgenic fly models 
overexpressing the naked expanded polyglutamine peptide also induce polyglutamine 
neurodegeneration (Kazemi-Esfarjani and Benzer, 2000; Marsh et al., 2000; 
Higashiyama et al, 2002; Kazantsev et al, 2002; Kazemi-Esfarjani and Benzer, 2002; 
Takeyama et al., 2002; Apostol et al., 2003; Nagai et al., 2003; Taylor et al., 2003). 
Characterization of GFP-polyglutamine transgenic flies 
Characterization of GFP-Q76 transgenic lines (both 14.2 and 19.2) showed that flies 
overexpressing the GFP-Q76 proteins displayed polyglutamine disease characteristics 
including the formation of NIs (Fig. 21B and C) and external eye depigmentation (Fig. 
2IE and F). Western blot analysis also showed that the GFP-Q76-FLAG fusion protein 
was expressed and SDS-insoluble NIs were formed as indicated by the presence of the 
protein complex in the SDS-PAGE stacking gel (Fig. 21G). Since the UAS-GFP-Q76-
FLAG line showed similar pathology as other expanded polyglutamine fly models such 
as the MJDtrQ78s model (Warrick et al., 1998), this line was validated for further study 
of polyglutamine NI proteins. 
For the control line of UAS-GFP-Q28-FLAG, flies overexpressing the 
unexpanded GFP-Q28-FLAG proteins showed no external eye depigmentation (Fig.22B). 
This phenotype was similar to other unexpanded polyglutamine fly models such as the 
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MJDtrQ27 model (Warrick et al., 1998). Moreover, Western blot showed that the GFP-
Q28-FLAG fusion protein was successfully expressed, but at a low level (Fig.22C). 
The successful generation of both UAS-GFP-Q76-FLAG (14.2 and 19.2) and 
UAS-GFP-Q28-FLAG (15.2) lines would facilitate direct visualization and isolation of 
polyglutamine NIs by flow cytometry. 
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Figure 21. Characterization of GFP-Q76 transgenic fly lines. UAS-GFP-Q76-FLAG 
lines were crossed to gmr-GAL4 line to drive the expression of GFP-Q76-FLAG protein in 
fly eyes. Two independent lines 14.2 and 19.2 showed formation of fluorescent NIs in 
third instar larval eye discs (white arrows, B and C). External eye degeneration indicated 
by the loss of eye pigmentation were also observed in adult fly eyes of both lines (E and F). 
No NI formation or eye degeneration were detected for the control transgenic flies 
overexpressing the GAL4 protein (A and D). (G) Western blot analysis showed that the 
GFP-Q76-FLAG fusion protein was expressed in both transgenic lines (lanes 2 and 3; 
arrow). Besides, some of the GFP-Q76-FLAG fusion proteins were SDS-insoluble and 
resided in the stacking gel (lanes 2 and 3; red bar), indicating the formation of SDS-
insoluble NIs. Antibody used was mouse anti-GFP (JL8; BD Biosciences). 
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Figure 22. Characterization of GFP-Q28 transgenic fly lines. UAS-GFP-Q28-FLAG 
line (15.2) were crossed to gmr-GAL4 line to drive the expression of GFP-Q28-FLAG 
protein in fly eyes. The external eye phenotype of the traasgenic line showed no 
degeneration (B), similar to the control fly overexpressing the GAL4 protein (A). (C) 
Western blot showed that the GFP-Q28-FLAG fusion protein of 32kDa was expressed in 
the transgenic line. Antibody used was mouse anti-GFP (JL8; BD Biosciences). 
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3.3 Characterization of the nuclear inclusion protein candidates 
The NI protein candidates identified by both "stacking gel approach" and “2D 
approach" were analyzed and documented (Tables 3-5). Among them, some of the 
candidates were chosen for further characterization based on several criteria, for example, 
whether they show neuronal expression, whether their cellular roles are related to neuronal 
functions, and whether they show significant differential 2D patterns. Based on these 
criteria, six of the NI protein candidates were chosen for further characterization to depict 
their roles in polyglutamine diseases. 
3.3.1 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
G A P D H was identified as a NI protein by both the "stacking gel approach" (section 
3.2.1, Table 3) and “2D approach" (section 3.2.2, Table 4). For the “2D approach”，it was 
identified as a differential spot for five times out of eight runs of 2D gels (Table 5), with an 
average of 2-fold increase in density for the 100% F A treated MJDtrQ61 sample when 
compared to the 0 % F A treated MJDtrQ61 sample (Table 4). 
G A P D H is a well-studied glycolytic enzyme that plays a key role in energy 
metabolism. G A P D H catalyzes the conversion of glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate in the glycolytic pathway . However, recent evidence suggest that it is 
a highly versatile molecule with diverse cellular roles including nuclear R N A export, D N A 
replication, D N A repair, exocytotic membrane fusion, cytoskeletal organization and 
phosphotransferase activity (Chuang and Ishitani, 1996; Sawa et al., 1997; Tatton et al., 
2000). Besides, G A P D H has been implicated in apoptosis and neurodegenerative diseases 
such as Alzheimer's disease and H D (Sirover, 1999; Tatton et al., 2000). 
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3.3.1.1 Confirmation of GAPDH as a NI protein 
G A P D H was identified as a NI protein candidate by both the “stacking gel approach” 
and "2D approach". The presence of G A P D H in NIs was further confirmed by 
immunostaining. Immunostaining was performed on head sections of adult MJDtrQ27 and 
MJDtrQ61 flies. For the control MJDtrQ27 sample, no NIs was formed and localization of 
both the MJDtrQ27 and G A P D H proteins were diffused in the cytoplasm (Fig. 23E and F). 
For the MJDtrQ61 sample, the MJDtrQ61 proteins were observed to localize to the nucleus 
(Fig. 23A), indicating the recruitment of the MJDtrQ61 proteins into the NIs. 
Immunostaining of G A P D H showed that G A P D H proteins colocalized with the M J D 
proteins in the nucleus, indicating the colocalization of the G A P D H proteins with the NIs 
(Fig. 23B). From the immunostaining results, it was further confirmed that G A P D H is a 
polyglutamine NI protein. 
3.3.1.2 Discussion 
In this study, G A P D H was found and confirmed as a polyglutamine NI protein in 
M J D fly model. Actually, G A P D H has previously been found to specifically interact with 
a number of expanded polyglutamine proteins including Huntingtin protein in H D (Burke 
et al, 1996)，Ataxin-1 protein in SCAl (Koshy et al., 1996), D R P L A protein in D R P L A 
(Burke et al., 1996), and androgen receptor in S B M A (Koshy et al., 1996). Besides, 
previous studies also found that NIs in H D mouse models (Sirover, 1999; Tatton et al., 
2000) and post mortem brains of M J D patients were immunopositive for G A P D H (Chuang 
and Ishitani, 1996; Tatton et al., 2000). Therefore, the result from this study agreed with 







































































































































































































































































































































































































































































































3.3.2 Receptor of activated protein kinase C (RACKI) 
R A C K I was identified as a NI protein by the “2D approach" for three times out of 
eight runs of 2D gels (section 3.2.2, table 5), with an average of 4-fold increase in density 
for the 100% F A treated MJDtrQ61 sample when compared to the 0 % FA treated 
MJDtrQ61 sample (Table 4). It is an adaptor protein for protein kinase C (PKC) and is 
involved in PKC-mediated signaling pathway (Battaini et al., 1999; McCahill et al., 2002). 
R A C K I has several independent protein-binding sites which can simultaneously interact 
with different signaling molecules and allow it to integrate inputs from multiple signaling 
pathways (Rodriguez et aL, 1999). 
3.3.2.1 Confirmation of RACKI as a NI protein 
3.3.2.1.1 Colocalization of RACKI with NIs 
R A C K I was identified as a NI protein by the "2D approach,,. The presence of 
R A C K I in NIs was further confirmed by immunostaining. Immunostaining was performed 
on head sections of adult MJDtrQ27 and MJDtrQ61 flies. For the control MJDtrQ27 
sample, no NIs was formed and localization of both the MJDtrQ27 and R A C K I proteins 
were diffused in the cytoplasm (Fig. 24E and F). For the MJDtrQ61 sample, the MJDtrQ61 
proteins were observed in the nucleus (Fig. 24A), indicating the recruitment of the 
MJDtrQ61 proteins into the NIs. R A C K I staining showed that R A C K I proteins 
colocalized with the MJDtrQ61 proteins in the nucleus, indicating the colocalization of 
R A C K I proteins with the NIs (Fig. 24B). From the immunostaining results, it was further 








































































































































































































































































































































































































































































































3.3.2.1.2 Formic Acid extracts RACKl from NIs 
Apart from immunostaining, the presence of R A C K l in NIs was further confirmed by 
another method. The rationale of this method is that if R A C K l is a NI protein, R A C K l 
could be extracted from the NIs by FA, as in the case for the expanded M J D proteins and 
another NI protein Hsp70 (section 3.1.1.3.1, Fig. 9). 
Proteins extracted from fly heads overexpressing the MJDtrQ61 protein were treated 
with 0%, 50% or 100% F A and then subjected to Western blotting analysis. Western blot 
showed that the amount of R A C K l monomer increased when treated with increasing 
concentration of F A (Fig. 25). Therefore, the result indicated that R A C K l was extracted 
from NIs by FA, and indirectly supported that R A C K l is a NI protein. 
3.3.2.2 Reduction of soluble R A C K l protein level in polyglutamine flies 
3.3.2.2.1 Soluble RACKl protein level was reduced in polyglutamine flies 
Since R A C K l was identified as a NI protein by the “2D approach" which was further 
confirmed by immunostaining and F A analysis, one would predict that the soluble amount 
of R A C K l protein would be reduced in polyglutamine flies due to its recruitment into the 
NIs. 
As predicted, soluble level of R A C K l protein in MJDtrQ61 flies (Fig. 26, lane 3) was 
much less than that in MJDtrQ27 flies (Fig. 26, lane 2). While almost no soluble R A C K l 
protein was detected in MJDtrQ78s flies (Fig. 26，lane 4). 
In the S B M A model, the soluble level of R A C K l protein in flies weakly 
overexpressing the expanded androgen receptor proteins ARtrQl 12w (Fig. 26, lane 6) was 
similar to flies overexpressing the unexpanded ARtrQl6 protein (Fig. 26, lane 5). However, 
almost no soluble R A C K l protein was detected in flies strongly overexpressing the 
expanded ARtrQl 12s protein (Fig. 26, lane 7). A similar result was also observed in the 
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MJDtrQGI MJDtrQGI MJDtrQ61 
0%FA 50%FA 100%FA 
參 , < RACKl 
F細r e 25. Level of soluble RACKl protein increases in polyglutamine flies after 
formic acid treatment. Proteins extracted from MJDtrQ61 flies were treated with 
different concentration of FA for solubilization of NI proteins. Western blotting 
showed that amount of soluble RACKl protein increased after treated with 100% FA 
Antibodies used was mouse anti-RACKl (BD Biosciences Pharaiingen). 
P , MJD MJD MJD AR AR AR SCA1 SCA1 
trQ27 trQ61 tiQ78s trQ16 trQ112w trQ112s Q30 Q82 
1 2 3 4 5 6 7 8 9 
iBBMHili"*"""""* m m m p n ^ ^ ― RACKl 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ tubulin 
Figure 26. Level of soluble RACKl protein decreases in flies overexpressing 
polyglutamine proteins of increasing length of polyglutamine repeats. Western blot 
analysis showed that soluble RACKl protein decreased in flies overexpressing 
polyglutamine proteins of increasing length of polyglutamine repeats in three 
polyglutamine fly models MJD, SBMA and SCAl. Antibodies used was mouse anti-
r A C K I (BD Biosciences Pharaiingen). The blot was stripped and reprobed with anti-E7 
(Developmental Studies Hybridoma Bank, University of Iowa, USA) for beta-tubulin as 
loading control. Fly lines used were flies overexpressing the truncated human Machado-
Joseph Disease proteins (MJDtr), the truncated human androgen receptor proteins (ARtr) 
and foil-length human SCAl proteins (SCAl). Control: control transgenic flies 
overexpressing the GAL4 protein. Q: glutamine repeat length. W: weak expression of 
the transgenes. S: strong expression of the transgenes. 
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SCAl model. Soluble R A C K l protein in flies overexpressing the expanded SCAIQ82 
protein (Fig. 26, lane 9) was relatively less than that of flies overexpressing the 
unexpanded SCA1Q30 protein (Fig. 26, lane 8). 
Therefore, the result showed that soluble amount of R A C K l protein was reduced in 
all three polyglutamine fly models including M J D , S B M A and SCAl. There was also a 
common trend that soluble R A C K l protein decreased in flies overexpressing 
polyglutamine proteins with increasing length of polyglutamine repeats, i.e. with 
increasing polyglutamine toxicity. 
3.3.2.2.2 RACKl transcript level remains unchanged in polyglutamine fly 
In order to investigate whether the change of R A C K l protein level in polyglutamine 
flies was due to the change of its transcript level, RT-PCR of R A C K l was performed. The 
RT-PCR results showed that RACKl transcript level remained unchanged in all three 
polyglutamine fly models including MJD, S B M A and SCAl (Fig. 27). Therefore, the 
result showed that the reduction of soluble R A C K l protein in expanded polyglutamine 
flies was not due to alteration of R A C K l transcription. 
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MJD MJD MJD ARtr ARtr ARtr SCAl SCAl 
Control 1^27 trQ61 trQ78s Qi6 Q112w Q112s Q30 Q82 
500 bp 
• • • 
Actin 
^ ^ H B H H I B H B I I H 300 bp 
Figure 27. Transcript level of RACKl remains nnchanged in polyglutamine fly 
models. RT-PCR showed that RACKl transcript level was similar among the 
control transgenic flies, flies overexpressing the 皿expanded polyglutamine 
proteins and flies overexpressing the expanded polyglutamine proteins in all three 
polyglutamine fly models MJD, SBMA and SCAl. Fly lines used were flies 
overexpressing the truncated human Machado-Joseph Disease proteins (MJDtr), the 
truncated human androgen receptor proteins (ARtr) and fiill-length human SCAl 
proteins (SCAl). Control: control transgenic flies overexpressing the GAL4 protein. 
Q： glutamine repeat length. W: weak expression of the transgenes. S: strong 
expression of the transgenes. Same set of samples were also amplified by actin 
primer as loading control. 
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3.3.2.3 Overexpression of RACKI partially suppresses polyglutamine 
degeneration 
According to the protein depletion theory, the recruitment of cellular proteins into the 
NIs would undermine their cellular activities, which may contribute to polyglutamine 
pathogenesis in some extent. In this sense, restoring the compromised activities of the NI 
proteins would in turn suppress polyglutamine toxicity. 
As a newly identified NI protein candidate, would overexpression of R A C K I 
suppress polyglutamine pathogenesis? Results of genetic crosses showed that 
overexpression of R A C K I in polyglutamine flies could partially suppress polyglutamine 
degeneration in all three polyglutamine fly models including M J D , S B M A and SCAl (Fig. 
28). Flies overexpressing the expanded polyglutamine proteins showed severe loss of red 
eye pigment (Fig. 28 A, D and F). Overexpression of R A C K ! in these flies partially 
suppressed polyglutamine degeneration as indicated by less eye pigment loss (Fig. 28 B, E 
and G). Overexpression of an unrelated protein GFP in polyglutamine flies had no 
suppression on eye degeneration (Fig. 28 C), suggesting that the suppression of R A C K I on 
polyglutamine degeneration was specific. The suppression was the strongest for the M J D 
model, followed by S B M A and SCAl models. The discrepancy of R A C K I suppression 
effect on different polyglutamine models may be due to the different toxicity and/or 
expression levels of the polyglutamine proteins. 
To conclude, the results agreed with the protein depletion theory that 
overexpression of R A C K I , as a NI protein, in polyglutamine flies could suppress 
polyglutamine pathogenesis. It also suggested the potential role of R A C K I in modifying 
polyglutamine toxicity. 
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MJDtrQ78s MJDtrQ78s MJDtrQ78s 
+ RACK1 +GFP 
ARtrQ112s O ^ A - ^ O O SCA1Q82 
ARtrQ11& +RACK1 SCA1Q82 + r a c k I amm _ _ 
Figure 28. Overexpression of RACKI partially suppresses polyglatamine degeneration in 
MJD, SBMA and SCAl polyglutamine fly models. The eye pigmentation was defined by a 5-
digit scale ranging from +2 to -2. “0” represents the unmodified eye depigmentation phenotype 
caused by the overexpression of different expanded polyglutamine disease proteins. ‘‘+，， 
denotes suppression, whereas “-’’ denotes enhancement. (A) MJDtrQ78s flies showed 
polyglutamine degeneration as indicated by loss of red eye pigment (score: 0). (B) 
Overexpression of RACKI in MJDtrQ78s fly partially suppressed the degeneration indicated 
by less eye pigment loss (score: +2). (C) Overexpression of an unrelated protein GFP, in fly 
had no modification on eye degeneration (score: 0) suggesting that the suppression of RACKI 
on polyglutamine degeneration was specific. Similarly, overexpression of RACKI in 
ARtrQ112s (E) and SCAlQ82s (G) flies could also suppress the eye degeneration partially 
(score: +1). Fly lines used were flies overexpressing the truncated human Machado-Joseph 
Disease proteins (MJDtr), the truncated human androgen receptor proteins (ARtr), and full-




Reduction of RACKl protein level in polyglutamine diseases 
R A C K l was found as a polyglutamine NI protein by the "2D approach" and 
confirmed to colocalize with NIs by immuno staining. Besides, Western blot showed that 
soluble R A C K l protein was reduced in all three polyglutamine fly models including MJD, 
S B M A and SCAl. In general, the reduction was glutamine-length dependent, i.e. longer 
glutamine repeats resulted in greater reduction of R A C K l protein level. The reduction of 
R A C K l protein in polyglutamine flies was not due to a change in the level of RACKl 
transcription. Hence, it was predicted that the reduction of R A C K l protein might be partly, 
if not all, due to the recruitment of R A C K l into the NIs. 
In fact, previous studies have observed a reduction of R A C K l level in brains of 
Alzheimer's disease patients (Battaini et al, 1999). However, they provided no insight into 
the reason of such reduction. The identification of R A C K l as a NI protein in this study 
may provide a possible explanation for the reduction of R A C K l level in Alzheimer's 
disease patients. Since the amyloid plaques, the protein inclusions similar to NIs, were also 
formed in Alzheimer's disease (Jellinger et al.，2002), it is speculated that the reduction of 
R A C K l level in Alzheimer's disease may be due to its recruitment into the amyloid 
plaques. 
Besides polyglutamine diseases and Alzheimer's disease, formation of protein 
inclusions is a common characteristic for a large group of protein conformation diseases 
also including Parkinson's disease and prion disease. Hence, the role of R A C K l in 
polyglutamine diseases and its presence in protein inclusion bodies may also provide 
insight into the pathogenic mechanisms of other members of the protein conformation 
diseases. 
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Roles of RACKl in polyglutamine pathogenesis 
Functionally, the reduction of soluble R A C K l in polyglutamine flies may impair its 
cellular activity as an adaptor protein in a number of R A C K l -mediated signaling pathways 
such as P K C signaling pathway. Indeed, the reduction of R A C K l protein level and its 
activity has been previously observed in some neurodegenerative diseases. For example, 
several studies documented a reduction of R A C K l protein level and aberrant P K C 
signaling pathway in Alzheimer's disease (Battaini et al., 1999). Besides, it was found that 
R A C K l immunoactivity was reduced in the brain cortex of aged rats, concomitantly with 
an impaired translocation in P K C activity, suggesting that the depletion of R A C K l would 
contribute to the functional impairment of P K C activity (Pascale et al., 1996). Since 
R A C K l level was observed to reduce in polyglutamine fly models, it was speculated that 
P K C signaling pathway or other R A C K l -mediated pathways might be impaired in 
polyglutamine diseases. 
In addition, the fact that overexpression of R A C K l in polyglutamine fly models could 
partially suppress polyglutamine pathogenesis also support the protein depletion theory 
that the depletion of cellular proteins into the NIs would contribute to polyglutamine 
pathogenesis while restoring the compromised activity of the NI proteins would suppress 
disease pathogenesis. In view of this, upregulating the activities of R A C K l and/or the 
R A C K l -mediated signaling pathways might be a potential way to modulate polyglutamine 
toxicity. 
Discussion on RACKl antibodies 
In this experiment, I used the monoclonal R A C K l antibodies, the mouse anti-RACKl 
(BD Biosciences Pharmingen) for detection of the Drosophila R A C K l protein. Sequence 
alignment showed that mouse and Drosophila R A C K l share high sequence homology of 
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about 76% (Fig. 29 I). According to the NCBI database, the molecular weight of both 
mouse and Drosophila R A C K l is around 36 kDa. Western blot showed that the antibodies 
could recognize a band of 36 kDa for mouse protein sample (Fig. 29 II, lane 1), indicating 
that the antibody was in good condition and specific for mouse R A C K l . However, a single 
band of around 55 kDa was instead detected for the Drosophila sample (Fig. 29 II, lane 2). 
By searching the N C B I and Flybase databases, only Drosophila R A C K l protein 
shows high sequence homology to mouse R A C K l . Thus, it eliminated the possibility that 
the antibodies recognize another Drosophila protein with higher homology to mouse 
R A C K l . In view of this, it was suggested that the Drosophila R A C K l protein sequence in 
the database might be incomplete. The actual Drosophila R A C K l might be of greater 
molecular weight of around 55 kDa. 
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CLUSTAL ¥ (1.82) Multiple sequence alignaexit (76% identity) 
Mouse MTEQjmEGTXKGHHGWVTQIiTTPQFPDMISASRDKTIMWKLTRDE-THYGIPQRAL 59 Fly MSETLQLHGTXIGHNGflVTQIiTHPKDPDTIISASEDKTLIVBKLTRDEETHYGYPQiaJL 60 
» ： » • 蓮 厘 直 垔 直 直 霣 • 霣 霣 霣 霣 霣 霣 霣 臺 ： 霣 置 夏 霣 厘 夏 夏 = • ： 霣 霣 霣 霣 霣 霣 霣 » 
House RGHSHFVSDVVISSDGQFAXSGSWDGTLRLTOLTTtm-lKHI? yGHTKDTLSVAFSSDMBQ 119 Fly YGHSHFISDWUSSDGHTiLSGSTOQTLELTOLiAGKTTERFEGHTKDVISVAFSADHRQ 120 
霣重夏夏霣：•霣•夏：霣霣霣霣：：霣霣重霣霣重重重重霣霣夏霣重Z：臺 .霣霣厘夏直霣霣置霣霣霣霣霣••霣霣：霣霣夏重 
House IVSGSRDKTIKL¥MTIJGVCKYTVQDESHSE¥V5CVHPSPHSSHPIIV5CG¥DKLVKV¥BX 179 Fly IVSGSRDKTIKLinnrLAECKFTIQEDGHrDirVSCTHFSPHHSMPIIVSCG¥DRTVKV¥KL 180 
買言 t^g^K^t^fc^B^^^fc^K^JB^K^K^fc • • ^^  • - • • W 算 ffc^ftJB"^  • IT 霄雷 言 Ifc^^^JfcJfc^ W^ W 嘗- W W If 盲 W 停 
House AMGKLKTHHIGHTGYUrrVTVBPDGBaiCASGGKDGQAlCLTOLHEGKHLYTLDGGDIHiL 239 Fly AMCKLKHHHHGHHG¥IirrVTVSPDGSLCTSGGKDSKAIX¥DLHDGKirLYTLEHHDINAL 240 
House CFSPHKT¥ICiATGPSIKITOLEGKIIVDELKQAVISTSSKAEPPQCTSLi¥SADGQrLF 299 Fly CFSPHRYinjCVAYGPSIKIflDLACKKTVEELRPEWSPTSKADQPQCISLAWSTDGQmF 300 
« « » « « » . » • »：«： »：». ：»«： » » m i l ： MHM»MM 
House AGYTDHLVRVTOVTIGTR 317 Fly AGYSDHTIRVWQVSVSAH 318 
j j Marker Mouse Fly 
1 丄 (kDa) 1 2 
96 — 
53 - ^ I H P - RACKI 
36 一 ^HMII^  _ Mouse 
RACKI 
28 — 
Figure 29. Characterization of mouse RACKI antibody. I. Sequence alignment 
showed a 76% identity between the mouse and fly RACKI proteins ("*" represents 
identical residues between the aligned sequences. ":" represents conserved residues 
between the aligned sequences."." represents semi-conserved residues between the 
aligned sequences). II. Western blotting showed a band, of 36 kDa matched to the 
predicted size of RACKI protein, was detected for the mouse protein sample (lane 1). 
Another band of around 55 kDa was detected for fly samples (lane 2). Antibodies used 
was mouse anti-RACKl (1:2000, BD Biosciences Pharmingen). 
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3.3.3 Warts (Wts) 
Wts was identified as a NI protein by the “stacking gel approach" (section 3.2.1, 
Table 3). Therefore, the fold of intensity change was not shown here. The confirmation of 
Wts in NIs by immunostaining had not yet been performed since Wts antibodies are not 
currently available. Wts encodes a serine/threonine kinase of the myotonic dystrophy 
protein kinase family. It is suggested to involve in a signaling pathway that coordinately 
regulates cell proliferation and apoptosis (Ryoo and Steller，2003). 
3.3.3.1 Overexpression of Wts partially suppresses polyglutamine 
degeneration 
Transgenic fly line overexpressing Wts is available and obtained from Dr. Iswar K. 
Hariharan (Tapon et al, 2002). Hence, the role of Wts in polyglutamine pathogenesis was 
studied by genetic analysis. 
According to the protein depletion theory, the depletion of Wts into the NIs might 
compromise its activity and contribute to polyglutamine pathogenesis in some extent. 
Hence, restoring the activities of Wts should in turn suppress polyglutamine toxicity. As 
predicted, overexpression of Wts in polyglutamine flies partially suppressed polyglutamine 
degeneration in all three polyglutamine fly models including MJD, S B M A and SCAl (Fig. 
30). The eye pigmentation was defined by a 5-digit scale ranging from +2 to -2. “0” 
represents the unmodified eye depigmentation phenotype caused by overexpression of 
different expanded polyglutamine disease proteins. “+，’ denotes suppression, whereas “-，， 
denotes enhancement. Flies overexpressing the expanded polyglutamine proteins showed 
polyglutamine degeneration indicated by severe loss of eye pigment (score: 0; Fig. 30 A, D 
and G). However, overexpression of Wts in these flies partially suppressed the 
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MJDtrQ78s MJDtrQ78s +Wte MJDtrQ78s +GFP ill 
ARtrQ112s ARtrQ112s+Wt5 ARtrQ112s +GFP 
• • • 
SCA1Q82 SCA1Q82 +Wts SCA1Q82 +GFP • • • 
Figure 30. Overexpression of Warts (Wts) partially suppresses polyglutamine 
degeneration in MJD, SBMA and SCAl polyglutamine fly models. The eye 
pigmentation was defined by a 5-digit scale ranging from +2 to -2. “0” represents the 
unmodified eye depigmentation phenotype caused by the overexpression of different 
expanded polyglutamine disease proteins. “+，’ denotes suppression, whereas 
denotes enhancement. (A) MJDtrQ78s fly showed polyglutamine degeneration as 
indicated by loss of red eye pigment (score: 0). (B) Overexpression of Wts in 
MJDtrQ78s fly partially suppressed the degeneration as indicated by less loss of eye 
pigment (score: +1). (C) Overexpression of an unrelated protein GFP, in polyglutamine 
fly had no suppression on eye degeneration suggesting that the suppression of Wts on 
polyglutamine degeneration was specific. Similarly, overexpression of Wts could also 
partially suppress the eye degeneration of ARtrQ112s (E) and SCAlQ82s (H) flies 
(score: +1). The suppression was also specific since overexpression of GFP in 
ARtrQllls (F) and SCA1Q82 (I) had no such suppression effect. Fly lines used were 
flies overexpressing the truncated human Machado-Joseph Disease proteins (MJDtr), 
the truncated human androgen receptor proteins (ARtr), and foil-length human SCAl 
proteins (SCAl). Q: glutamine repeat length, s: strong expression of the transgenes. 
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degeneration as indicated by less loss of red eye pigment (score: +2 for the M J D model, fig. 
30B; and from 0 to +1 for the SCAl and S B M A models, fig. 30 E and H). Overexpression 
of an unrelated protein GFP in these flies had no suppression on eye degeneration (Fig. 30 
C, F and I), suggesting that the suppression of Wts on polyglutamine degeneration was 
specific. Therefore, the result suggested the potential role of Wts in modifying 
polyglutamine toxicity. 
3.3.3.2 Wts mutant slightly enhances polyglutamine degeneration 
According to the protein depletion theory, further reduction of the activities of NI 
proteins would enhance polyglutamine pathogenesis if those NI proteins are essential to the 
disease pathogenesis. As Wts was identified to be a NI protein by the "stacking gel 
approach" and its overexpression resulted in suppression of polyglutamine degeneration, 
would mutation of Wts further enhance polyglutamine degeneration? The eye pigmentation 
was defined by a 5-digit scale ranging from +2 to -2. “0” represents the unmodified eye 
depigmentation phenotype caused by the overexpression of different expanded 
polyglutamine disease proteins. “+’，denotes suppression, whereas “-，’ denotes 
enhancement. As predicted, mutation of Wts in MJDtrQ78s fly slightly enhanced 
polyglutamine degeneration indicated by more eye pigment loss (score: -1; Fig. 3IB), 
when compared to fly overexpressing the MJDtrQ78s protein alone (score: 0; Fig. 31 A). 
Furthermore, the enhancement caused by Wts mutation could be rescued by overexpression 
of Wts (score:+1; Fig. 31C). 
In short, the modification of polyglutamine pathogenesis by both overexpression and 
mutation of Wts agreed to the protein depletion theory and suggested the potential role of 
Wts as a polyglutamine disease modifier. 
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3.3.3.3 Genetic analysis of Warts pathway in polyglutamine pathogenesis 
Previous studies have suggested that Wts was involved in a pathway controlling 
both cell cycle and apoptosis (Ryoo and Steller, 2003). Meanwhile, apoptosis was found to 
be critical in polyglutamine neurodegeneration (Lipinski and Yuan, 2004). As Wts was 
identified as a NI protein and its ability to modify polyglutamine degeneration, it was 
worthwhile to further investigate the roles of Wts pathway in polyglutamine pathogenesis. 
By making use of fly genetics, modification effect of other components of the Wts 
pathway on polyglutamine disease was examined. 
According to the previously suggested pathway, Wts works together with Hpo and 
Sav to define a signaling pathway that coordinately regulates cell proliferation and 
apoptosis (Fig. 32) (Ryoo and Steller, 2003). Hpo encodes a serine/threonine kinase, while 
Sav acts as a scaffold protein that binds to Wts and Hpo. This Hpo-Sav-Wts complex 
allows Hpo to efficiently phosphorylate Wts. Therefore, Hpo, Sav, and Wts interact with 
each other both physically and functionally (Tapon et al., 2002; Rothenberg and Jan, 2003; 
Ryoo and Steller, 2003; W u et al., 2003). It was suggested that this protein complex 
phosphorylates multiple targets including Sav, Wts and DIAPl. Phosphorylation of DIAPl, 
an apoptotic inhibitor, renders it unstable and sensitizes cells to apoptosis (Tapon et al., 
2002; Rothenberg and Jan, 2003; Ryoo and Steller, 2003; W u et al, 2003) 
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MJDtrQ78 MJDtrQ78 MJDtrQ78 MJDtrQ78 
+ wts 腕 1H + vvts 舶 1H + wts + wfeMGIH + saV 
Figure 31. Warts mutant slightly enhances polyglutamine degeneration. The eye 
pigmentation was defined by a 5-digit scale ranging from +2 to -2. “0” represents the 
unmodified eye depigmentation phenotype caused by the overexpression of different 
expanded polyglutamine disease proteins. “+，，denotes suppression, whereas “-” 
denotes enhancement. (A) MJDtrQ78s fly showed eye degeneration indicated by loss 
of red eye pigment (score: 0). (B) Expression of Warts mutant Wts^Gm MJDtrQ78s 
fly slightly enhanced polyglutamine degeneration shown by greater loss of red eye 
pigment (score: -1). However, co-overexpressing Wts (C) and Sav (D) with Wts^^'^ 
in polyglutamine fly could rescue the enhanced polyglutamine degeneration induced by 
WtsMGiH，indicated by restoration of the red eye pigment (score: +1). The rescuing 
effect of Sav was stronger than that of Wts (score: +2). 
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Figure 32. Regulation of cell cycle and apoptosis by Hpo-Sav-Wts complex. 
Hpo, Sav and Wts physically interact to form a protein complex. Hpo and Wts have 
protein kinase activities. The Hpo-Sav-Wts complex phosphorylates multiple targets, 
including Sav, Wts and DIAPl. Hpo-Sav-Wts kinase activity is also important for the 
transcriptional repression of cyciin E and diapl, but the protein that mediates such 
activity is not known. Phosphorylation of DIAPl makes it unstable, potentially 
sensitizing cells to apoptosis. (Adapted from Ryoo and Steller, 2003, Nature Cell 
Biology 5: 853-855) 
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3.3.3.3.1 Overexpression of Salvador partially suppresses polyglutamine 
degeneration 
Since Sav acts as a scaffold protein that physically interacts with Wts and works with 
Wts in the same signaling pathway, it is predicted that Sav would behave similarly as Wts 
on modifying polyglutamine toxicity. By crossing a fly line overexpressing Sav (Tapon et 
al., 2002) to polyglutamine flies, polyglutamine degeneration was partially suppressed in 
all three polyglutamine models including M J D , S B M A and SCAl (Fig. 33). Therefore, the 
result suggested the potential role of Sav in modifying polyglutamine pathogenesis. 
Besides, overexpression of Sav (Fig. 34C) in MJDtrQ78s fly resulted in stronger 
restoration of red eye pigment than that of Wts (Fig. 34B). Therefore, it showed that Sav 
had a stronger suppression on polyglutamine degeneration than that of Wts. However, it 
was also possible that such discrepancy was due to the different expression level of the Sav 
and Wts trans genes. Moreover, overexpression of 2 copies of Sav transgenes in MJDtrQ78s 
fly resulted in even stronger suppression on polyglutamine degeneration (Fig. 34D). 
In addition, the enhancement of polyglutamine degeneration by Wts mutation could 
be rescued by overexpression of Sav (Fig. 3ID). This agreed with the proposed pathway 
that there was genetic interaction between Sav and Wts. The rescuing effect of Sav was 
even stronger than that of Wts (Fig. 31C). The fly anti-Sav antibodies were being produced 
for further study the role of Sav in polyglutamine diseases. 
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iyiJDtrQ78s MJDtrQ78s +Sav MJDtfQ78s -i^FP 
H ^ H I ^ H ^ I H • • • 
ARtrQ112s ARtfQ112s + Sav ARtrQ112s +GFP  
• • • 
SCA1Q82 SCA1Q82 + Sav SCA1Q82 +GFP  
• • • 
Figure 33. Overexpression of Salvador (Sav) partially suppresses polyglutamine 
degeneration in MJD, SBMA and SCAl polyglutamme fly models. The eye 
pigmentation was defined by a 5-digit scale ranging from +2 to -2. “0” represents the 
unmodified eye depigmentation phenotype caused by the overexpression of different 
expanded polyglutamine disease proteins. “+” denotes suppression, whereas “-” denotes 
enhancement. (A) MJDtrQ78s fly showed polyglutamine degeneration as indicated by 
loss of red eye pigment (score: 0). (B) Overexpression of Sav in MJDtrQ78s fly partially 
suppressed the degeneration indicated by less loss of eye pigment (score: +1). (C) 
Overexpression of an unrelated protein GFP, in polyglutamine fly had no suppression on 
eye degeneration suggesting that the suppression of Sav on polyglutamine degeneration 
was specific. Similarly, overexpression of Sav could also partially suppress the eye 
degeneration of the ARtrQ112s 如 and SCAlQ82s (H) flies (score: +1). The suppression 
was also specific since overexpression of GFP in ARtrQ112s (F) and SCA1Q82 (I) flies 
had no such suppression effect. Fly lines used were flies overexpressing the truncated 
human Machado-Joseph Disease proteins (MJDtr), the truncated human androgen 
receptor proteins (ARtr), and foil-length human SCAl proteins (SCAl). Q: glutamine 
repeat length, s: strong expression of the transgenes. 
117 
MJDtrQ78s MJDtrQ78s+Wt5 MJDtrQ78s+Sav MJDtrQ78s+2Sav 
• • • • 
Figure 34. Salvador (Sav) suppresses polyglutamine degeneration more effectively than 
Warts (Wts). The eye pigmentation was defined by a 5-digit scale ranging from +2 to -2. “0” 
represents the unmodified eye depigmentation phenotype caused by the overexpression of 
different expanded polyglutamine disease proteins. “+’，denotes suppression, whereas 
denotes enhancement. (A) MJDtrQ78s fly showed eye degeneration as indicated by loss of 
red eye pigment (score: 0). Overexpression of Sav in MJDtrQTSs fly suppressed the eye 
degeneration more effectively (score: +1, C) than that of Wts (score: + 1.5, B) by comparing 
the degree of restoration of red eye pigment. Overexpression of 2 copies of Sav transgenes in 
MJDtrQ78s fly resulted in even stronger suppression of eye degeneration (score: + 2，D). 
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3.3.3.3.2 Hpo mutant slightly enhances polyglutamine degeneration 
Hpo is a serine/threonine kinase which physically interacts with both Wts and Sav, 
and phosphorylates Wts for the downstream regulation of cell cycle arrest and apoptosis. It 
was shown above that overexpression of Wts and Sav could both suppress polyglutamine 
degeneration. Therefore, it was predicted that Hpo would also behave similarly as Wts and 
Sav. 
Since there is no Hpo overexpressing transgenic line available but Hpo mutant line, 
the Hpo mutant line was crossed to polyglutamine flies (Fig. 35). Expression of Hpo 
mutant in MJDtrQ61 fly strongly enhanced polyglutamine degeneration (Fig. 35C), as 
indicated by the loss of red eye pigment as compared to fly expressing the Hop mutant 
UAS-Hpo auto (III) only (Fig. 35D), with the degree of pigment loss similar to the more 
toxic polyglutamine fly model MJDtrQ78s (Fig. 35E). However, expression of Hpo mutant 
alone in flies had dominant effect as indicated by the reduced eye size and rough eye 
phenotype (Fig. 35D). The result suggested that Hpo was also a potential modifier of 
polyglutamine pathogenesis. 
3.3.3.3.3 Overexpression of DIAPl partially suppresses polyglutamine 
degeneration 
DIAPl is proposed to be a cell death inhibitor downstream of the Wts pathway. 
Overexpression of DIAPl in MJDtrQ78s fly partially suppressed polyglutamine 
degeneration as indicated by less loss of eye pigment (Fig. 36C), as compared to the 
MJDtrQ78s fly. Moreover, the suppression was specific (Fig. 36B) since overexpression of 
an unrelated protein GFP had no such effect. Since DIAPl is proposed to be a cell death 
inhibitor (Wang et al., 1999b), it is reasonable that overexpression of DIAPl could inhibit 
cell death and suppress polyglutamine degeneration. 
119 
MJDtrQGI + UAS-
Control MJDtrQGI Hpo auto (III) UAS-Hpo auto (III) MJPtrQ78s 
_••圓• 
Figure 35. Hop mutant strongly enhances polyglutamine degeneration. MJDtrQ61 fly at 
3-day old showed no external eye degeneration (B), as compared to the control transgenic fly 
overexpressing the GAL4 protein (A). Expression of Hop mutant UAS-Hpo auto (III) in 
MJDtrQ61 fly strongly enhanced eye degeneration indicated by the loss of red eye pigment (C) 
as compared to fly expressing the Hop mutant UAS-Hpo auto (III) only (D), with the degree of 
pigment loss similar to the more toxic polyglutamine fly model MJDtrQ78s. Expression of 
Hpo mutant alone in flies had dominant effect as indicated by the reduced eye size and rough 
eye phenotype (D). 
MJDtrQ78s MJDtrQ78s + GFP MJDtrQ78s+ DIAP1 I^BII 
Figure 36. Overexpression of DIAPl partially suppresses polyglutamine 
degeneration. The eye pigmentation was defined by a 5-digit scale ranging from +2 to 
-2. “0” represents the unmodified eye depigmentation phenotype caused by the 
overexpression of different expanded polyglutamine disease proteins. “+” denotes 
suppression, whereas “-” denotes enhancement. MJDtrQ78s fly showed eye 
degeneration indicated by loss of red eye pigment (score: 0’ A). Overexpression of 
DIAPl (C) in MJDtrQ78s fly partially suppressed the degeneration indicated by less 
eye pigment loss (score: +1). Overexpression of an unrelated protein GFP, in 
polyglutamine fly had no suppression on eye degeneration (B) suggesting that the 
suppression of DIAPl on polyglutamine pathogenesis was specific. 
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3.3.3.4 Discussion 
Wts was found to be a polyglutamine NI protein by the "stacking gel approach". 
Besides, overexpression of Wts could partially suppress polyglutamine pathogenesis in all 
three polyglutamine fly models including M J D , S B M A and SCAl, which also agreed to 
the protein depletion theory. 
Moreover, genetic crosses showed that overexpression of Sav could also suppress 
polyglutamine pathogenesis in M J D , S B M A and SCAl models, similar to that of Wts. The 
suppression of polyglutamine pathogenesis by Sav was even stronger than that of Wts, 
which agreed to the proposed pathway that Sav worked to reinforce the activity of Wts. 
However, it was also possible that such discrepancy was due to the different expression 
level of the Sav and Wts transgenes. Furthermore, the enhanced polyglutamine 
degeneration caused by Wts mutation could be rescued by overexpression of Sav, 
suggesting the genetic interaction between Sav and Wts. 
Hpo is another member in the Wts pathway. Mutation of Hpo in polyglutamine fly 
enhanced polyglutamine degeneration, which was in accordance with the case of Wts and 
Sav that their overexpression resulted in suppression of polyglutamine degeneration. 
To conclude, several components of the Wts pathway including Wts, Sav, Hpo and 
DIAPl were shown to have modification on polyglutamine pathogenesis. However, the 
exact roles of the Hpo-Sav-Wts complex in polyglutamine pathogenesis still need to be 
further investigated. Besides the proposed pathways of regulating cell proliferation and 
apoptosis, the Hpo-Sav-Wts complex might also play their roles in polyglutamine 
pathogenesis through other unidentified pathways. 
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3.3.4 Alcohol dehydrogenase (Adh) 
Adh was identified as a NI protein by the "2D approach" for five times out of eight 
runs of 2D gels (section 3.2.2, Table 5), with an average of 1.5-fold increase in density for 
the 100% F A treated MJDtrQ61 sample when compared to the 0 % F A treated MJDtrQ61 
sample (Table 4). However, the confirmation of Adh in NIs by immuno staining had not yet 
been performed since fly Adh antibodies are not currently available. 
Adh is a well-known enzyme responsible for ethanol metabolism. During the 
metabolism, Adh converts ethanol into acetaldehyde, while the co-factor N A D + is reduced 
to N A D H (Crabb et al., 2004). Since Adh activity can be easily measured by the well-
established Adh assay (Aquadro et al., 1990), the role of Adh in polyglutamine 
pathogenesis was studied by investigating its activity in polyglutamine flies. 
3.3.4.1 Adh activity is reduced in polyglutamine flies 
The Adh activity was measured as the rate of formation of N A D H indicated by the 
rate of increase of the absorbance at 340 run. The assay showed that Adh enzyme activity 
was reduced by 35% in MJDtrQ78s flies (Fig. 37B) and by 53% in MJDtrQ61 flies (Fig. 
38B), as compared to the control MJDtrQ27 flies (Fig. 37A and 38A). The experiments 
were repeated twice and similar results were obtained. 
3.3.4.2 Overexpression of Hsp70 partially restores the reduced Adh 
activity in polyglutamine flies 
Previous studies found that overexpression of Hsp70 resulted in strong suppression of 
polyglutamine pathogenesis (Warrick et al., 1999; Chan et al., 2000; Fernandez-Funez et 
al., 2000; Kazemi-Esfarj ani and Benzer, 2000; Cummings et al, 2001; Chan et al., 2002c). 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and increase the solubility of the NI proteins, leading to the release of subsets of essential 
NI proteins back to their physiological subcellular compartments. This would partially 
restore the activities of the NI proteins and result in suppression of polyglutamine diseases 
(Chan et al., 2000; Chan et al., 2002c). 
As Adh was identified as a potential NI protein and its activity was shown to be 
compromised in polyglutamine fly models, would overexpression of Hsp70 restore Adh 
activity? The Adh assay showed that after overexpression of Hsp70, the Adh activity in 
MJDtrQ78s flies was restored from 65% to 90% as compared to the activity in the 
MJDtrQ27 flies (as 100%) (Fig. 37C), whereas the restoration was from 47% to 58% for 
the MJDtrQ61 fly model (Fig. 38C). Therefore, the result showed that the reduction of Adh 
activity in polyglutamine flies could be partially restored by overexpression of Hsp70. 
3.3.4.3 Discussion 
Adh was identified as a polyglutamine NI protein by the ‘‘2D approach". The Adh 
assay showed that Adh activity was reduced in polyglutamine flies. However, the 
compromised Adh activity in polyglutamine flies could be partially restored by 
overexpression of molecular chaperones of Hsp70. 
Since it was suggested that those subsets of cellular proteins released from the NIs by 
molecular chaperones with restoration of activities would be the ones that are critical in 
polyglutamine pathogenesis (Chan et al, 2000; Chan et al., 2002c), the partial restoration 
of Adh activity by overexpression of Hsp70 suggest that Adh would be one such factor. 
As Adh is responsible for regulating alcohol metabolism, any defect in Adh activity 
would lead to impaired alcohol metabolism. However, there is still no study showing 
insight into the correlation of alcohol metabolism and neurodegenerative diseases. One of 
the possible ways that Adh involves in polyglutamine diseases may be due to the defect of 
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energy metabolism caused by impaired alcohol metabolism. However, alcohol may not be 
a major energy source in both humans and Drosophila models. Therefore, decrease in Adh 
activity may not contribute significantly to energy deprivation. In view of this, Adh may 
implicate in polyglutamine pathogenesis through other novel roles or pathways. 
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3.3.5 Genetic analysis of other NI protein candidates 
3.3.5.1 Overexpression of CG7920 protein partially suppresses 
polyglutamine degeneration 
CG7920 was identified as a NI protein by the “2D approach" for two times out of 
eight runs of 2D gels (section 3.2.2, Table 5)，with an average of 2-fold increase in density 
for the 100% F A treated MJDtrQ61 sample when compared to the 0 % FA treated 
MJDtrQ61 sample (Table 4). However, the confirmation of CG7920 protein in NIs by 
immunostaining had not yet been performed since its antibodies are not currently available. 
CG7920 is a gene with putative 4-hydroxybutyrate Co A transferase activity involved in 
acetyl-CoA metabolism (Wayne and Mclntyre, 2002). However, this gene has not yet been 
characterized in detail. 
Results of genetic crosses showed that overexpression of CG7920 protein in 
polyglutamine flies partially suppressed polyglutamine degeneration in all three 
polyglutamine fly models including M J D , S B M A and SCAl (Fig. 39). The suppression of 
CG7920 on polyglutamine degeneration was specific since overexpression of an unrelated 
protein GFP in polyglutamine flies had no such effect. Therefore, the result suggested the 
potential role of CG7920 in modifying polyglutamine pathogenesis and also agreed to the 
protein depletion theory that restoring the activities of NI protein would suppress 
polyglutamine pathogenesis. 
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•MJDtrQ78s +CG7920 MJDtrQ78s 
ifBl flk 
ARtrQl 12s ARtrQl 12s + CG7920 ARtrQ112s +GFP 
• • • 
SCA1Q82 SCA1Q82 + CG7920 SCA1Q82 -KSFP 
^ ^ I H H ft^HEJ I ^ ^ H H 
Figure 39. Overexpression of CG7920 partially suppresses polyglutaiiiine 
degeneration in MJD, SBMA and SCAl polyglutamine fly models. The eye 
pigmentation was defined by a 5-digit scale ranging from +2 to -2. “0” represents the 
unmodified eye depigmentation phenotype caused by the overexpression of different 
expanded polyglutamine disease proteins. “+,，denotes suppression, whereas “-，， 
denotes enhancement. (A) MJDtrQ78s fly showed polyglutamme degeneration as 
indicated by loss of red eye pigment (score: 0). (B) Overexpression of CG7920 in 
MJDtrQ78s fly partially suppressed the degeneration indicated by less loss of eye 
pigment (score: +2). (C) Overexpression of an unrelated protein GFP, in 
polyglutamine fly had no suppression on eye degeneration suggesting that the 
suppression effect of CG7920 on polyglutamine degeneration was specific. Similarly, 
overexpression of CG7920 could also partially suppress the eye degeneration of 
ARtrQl 12s (E) and SCAlQ82s (H) flies (score: +1). The suppression was also 
specific since overexpression of GFP in ARtrQl 12s (F) and SCA1Q82 (I) had no such 
suppression effect. Fly lines used were flies overexpressing the truncated human 
Machado-Joseph Disease proteins (MJDtr), the truncated human androgen receptor 
proteins (ARtr), and fiill-length human SCAl proteins (SCAl). Q: glutamine repeat 
length, s: strong expression of the transgenes. 
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3.3.5.2 Pten dsRNA slightly enhances polyglutamine degeneration 
Pten was identified as a NI protein by the “2D approach" for once (section 3.2.2, 
Table 4), with an 1.2-fold increase in density for the 100% F A treated MJDtrQ61 sample 
when compared to the 0 % F A treated MJDtrQ61 sample. However, the confirmation of 
Pten in NIs by immuno staining had not yet been performed since its antibodies are not 
currently available. 
Pten encodes a product with phosphatase activity involved in insulin receptor 
signaling pathway (Li et al., 2003). Pten was detected in most neurons, including granule 
neurons in the olfactory bulb, pyramidal neurons in the cortex, cerebellar Purkinje and 
granule neurons (Lachyankar et al., 2000). Adult Pten knockout mice demonstrated that 
Pten regulates migration of precursor cells in the subventricular zone of the olfactory bulb 
(Li et al., 2002). Collectively, these studies suggest that Pten is a master regulator in 
developing brain, probably through its role in insulin receptor signaling pathway. 
Result of genetic cross showed that overexpression of Pten dsRNA in MJDtrQ61 flies 
further enhanced polyglutamine degeneration (Fig. 40), as indicated by patches of eye 
pigmental loss and disorganized ommatidia when compared to the MJDtrQ61 flies (Fig. 
40B). Therefore, the result suggested the potential role of Pten in modifying polyglutamine 
pathogenesis and also agreed to the protein depletion theory that further reducing the 
activities of NI protein would enhance polyglutamine pathogenesis. 
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• �… � MJDtrQGI + 
Control IWUDtrQ61 Pten8548 lii 
Figure 40. Overexpression of Pten dsRNA slightly enhances polyglutamine 
degeneration. MJDtrQ61 fly at 3-day old showed no eye degeneration (B) as 
compared to the control transgenic fly overexpressing the GAL4 protein (A). 
Overexpression of Pten dsRNA Pten8548 (C) in MJDtrQ61 fly slightly 
enhanced polyglutamine degeneration indicated by patches of pigment loss. 
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3.3.6 Summary 
Among the list of identified NI protein candidates, G P A D H was found as a NI protein 
by both the "stacking gel approach" and “2D approach". Furthermore, G A P D H was 
confirmed to colocalize with NIs by immunostaining. Indeed, previous studies have also 
found G A P D H in the NIs of H D mouse models (Sirover, 1999; Tatton et al., 2000) and 
post mortem brains of M J D patients (Chuang and Ishitani, 1996; Tatton et al., 2000). 
Therefore, G A P D H serve as an example to show that both approaches are feasible for 
identification of NI proteins. 
The identification of R A C K l as a NI protein and the reduction of its protein level in 
polyglutamine flies may suggest an impairment of its normal activity as an adaptor protein 
in a number of RACKl-mediated signaling pathways, such as P K C signaling pathway. 
This might be one of the underlying causes of polyglutamine pathogenesis. In addition, 
overexpression of R A C K l partially suppressed polyglutamine pathogenesis also supports 
the protein depletion theory. In view of this, increasing the activities of R A C K l and/or the 
RACKl-mediated signaling pathways would be a potential way to modulate polyglutamine 
pathogenesis. 
For another NI protein candidate Wts and other players in the Wts pathway, genetic 
analysis showed that the Hpo-Sav-Wts complex can modify polyglutamine toxicity. It was 
proposed that Wts pathway was involved in regulation of cell proliferation and apoptosis. 
However, the Hpo-Sav-Wts complex may also involve in polyglutamine pathogenesis 
through other unidentified pathways. 
For Adh, its activity was found to reduced in polyglutamine flies. However, partial 
restoration of Adh activity by overexpression of Hsp70 provided an indirect confirmation 
of Adh as a NI protein and also suggested the essential role of Adh in polyglutamine 
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pathogenesis. Nevertheless, there is still no study showing insight into the correlation of 
alcohol metabolism and neurodegenerative diseases. 
For the less characterized NI candidates CG7920 and Pten, genetic analysis showed 
that both of them had potential modifying effect on polyglutamine diseases. Pten was 
found as a master regulator in developing brain, probably through its role in insulin 
receptor signaling pathway; whereas CG7920 has not been characterized in detail It is 
speculated that the activities of Pten in brain development would be compromised if it is 
depleted into the NIs, which might contribute to polyglutamine pathogenesis. However, the 
exact mechanisms of these proteins in modifying polyglutamine diseases need further 
investigation before firm conclusion can be drawn. 
Except G A P D H and R A C K I , the presence of other candidates in NIs had not been 
confirmed by immunostaining since their antibodies are not currently available. Therefore, 
the presence of these candidates in NIs is required to further confirm in the future. In 
general, the results showed that the depletion of a wide range of cellular proteins into the 




4.1 Protein depletion theory 
According to the protein depletion theory, the recruitment of cellular protein into the 
NIs would compromise their normal activities and thus cause disturbance to cellular 
processes and contribute to polyglutamine toxicity (Yamada et al., 2000; Fischbeck, 
2001; Michalik and Van Broeckhoven, 2003; Everett and Wood, 2004). In view of this, 
identification of NI proteins would provide insight into novel pathogenic pathways and 
the corresponding therapeutic interventions of polyglutamine diseases. Thus, this project 
aimed to study polyglutamine disease by identification of the polyglutamine NI proteins. 
A long list of 81 NI protein candidates had been identified (38 from “stacking gel 
approach" and 44 from “2D approach"). The newly identified NI protein candidates 
possess diverse cellular roles such as metabolic enzymes, kinases, phosphatases, 
signaling molecules and proteosome components (Table 4 and 5). According to the 
protein depletion theory, the recruitment of such a wide range of cellular proteins into the 
NIs would impair multiple cellular pathways. These pathways could act independently or 
more likely, interact and enhance each other to cause cellular disturbance. The 
accumulation of cellular damage may eventually lead to dysfunction and ultimately 
neuronal cell death in polyglutamine diseases (McCahill et al., 2002; Everett and Wood, 
2004; Lipinski and Yuan, 2004). 
By identifying new NI proteins, novel pathogenic pathways were revealed from this 
study. For example, R A C K l level was observed to reduce in polyglutamine fly models and 
hence it is speculated that P K C signaling pathway or other R A C K l -mediated pathways 
might be impaired in polyglutamine diseases. 
Furthermore, potential therapeutic interventions could be discovered by restoring the 
compromised activities of the NI proteins through preventing its recruitment into the NIs 
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or manipulating their corresponding cellular pathways. Indeed, it has been shown that 
preventing the recruitment of G A P D H into the NIs by introducing peptides could 
upregulate G A P D H activity and modulate polyglutamine toxicity (Ishitani et al., 2003). 
4.2 Comparison of different approaches for identification of NI 
proteins 
In this study, a proteomic approach was adopted to study polyglutamine diseases, 
whereas conventional methods for studying polyglutamine diseases are mainly based on 
microarray (Chan et al., 2002a; Luthi-Carter et al., 2002; Sipione et al, 2002) and genetic 
modifier screening (Kazemi-Esfarjani and Benzer, 2000; Faber et al., 2002; Kazemi-
Esfarj ani and Benzer, 2002). However, identification of NI proteins in this study as a hint 
to explore novel polyglutamine pathogenic mechanisms and therapeutic interventions 
would complement with the existing methods in identifying disease interacting genes and 
modifiers. Therefore, the present study may contribute to a more comprehensive 
understanding of the polyglutamine pathogenic mechanisms. 
Different approaches have been adopted to identify NI proteins in this study. As an 
initial attempt, I made use of the SDS-insoluble properties of NIs for identification of NI 
proteins. Since it was shown that NIs are SDS-insoluble and resided in the SDS-PAGE 
stacking gel (Chan et al., 2000), it should be feasible to identify the NI proteins by cutting 
out the stacking gel for in-gel digestion and mass spectrometric identification. This 
approach was named as the "stacking gel approach". Using this approach, 38 NI candidates 
have been identified (Table 3). Four of them have been previously found to colocalize with 
NIs (Table 3). Hence, they served as positive indicators showing that this approach is 
feasible for identifying NI proteins. Although the "stacking gel approach" is convenient 
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and quick for identification of NI proteins, the whole NI complex containing mixture of 
proteins was subjected to mass spectrometric analysis rather than the individual NI protein. 
In view of this, a more precise and systematic method was also performed to identify NI 
proteins. 
As it has been proved that F A was able to dissolve NIs from flies (section 3.1.1.3), 
NIs were first dissolved by F A into individual NI protein prior to electrophoretic 
separation. The F A treated samples were separated by 2D gel electrophoresis, named as the 
"2D approach". Using this approach, 44 potential NI proteins were identified. Among them, 
three proteins have been previously found to colocalize with NIs. Therefore, it again 
validates the “2D approach" as a feasible method for identification of NI proteins. 
However, a significant differential protein pattern is required for this method and 
sometimes potential NI proteins may be overlooked if their differential patterns are just 
subtle. 
The use of both approaches can complement each other to give a more complete list 
of NI proteins. However, some false positive NI protein candidates might be identified. 
Therefore, the candidates need to be further confirmed in NIs by other analysis such as 
immimostaining (sections 3.3.1.1 and 3.3.2.1.1). 
Although a long list of 81 NI proteins candidates has been identified by the two 
approaches, it is speculated that the NI protein list is still not yet saturated since there was 
only a small number of overlapping candidates being identified by both approaches, such 
as G A P D H . Therefore, other methodologies which can complement with the present 
approaches in identifying NI proteins can be adopted to give a further complete list of NI 
proteins. For example, flow cytometry can be used to detect and isolate fly NIs. This 
approach allows a large amount of NIs to be isolated routinely. The newly generated GFP-
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polyglutamine fly models can also be used to facilitate the detection and isolation of NIs 
based on the intrinsic fluorescent nature of the GFP-polyglutamine proteins. 
4.3 Long-term significance 
A growing number of neurodegenerative diseases have been found to result from 
polyglutamine expansion, as well as with an increasing number of infected individuals 
worldwide (Zoghbi and Orr, 2000). Despite of the intensive studies by different research 
groups over the past 15 years since the discovery of polyglutamine diseases (La Spada et 
al., 1991), the pathogenic mechanisms is just to be revealed. Moreover, effective 
intervention methods have not yet been discovered. 
According to the protein depletion theory, the depletion of cellular proteins into the 
NIs would undermine their activities and cause cellular disturbance, which may contribute 
to polyglutamine diseases pathogenesis. Thus, the present study adopted a new approach to 
study polyglutamine diseases by identification of NI proteins. By identifying a more 
complete list of NI proteins, novel pathogenic pathways have been identified. Moreover, 
potential therapeutic interventions could also be explored by upregulating the activities of 
the newly identified NI proteins. Furthermore, the formation of protein inclusions is a 
common cause of a large group of protein conformation diseases, including Parkinson's 
disease, Alzheimer's diseases and prion disease, besides polyglutamine diseases (Heintz 
and Zoghbi, 1997). Therefore, the approach used in this study can also be applied to the 
study of these diseases. 
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4.4 Future studies 
4.4.1 Characterization of other NI protein candidates 
From the present study, a long list of 81 NI proteins has been identified. However, 
only six of them have been further characterized. Therefore, the roles of other NI protein 
candidates in polyglutamine diseases still wait to be further studied. Besides, some of the 
NI proteins candidates further characterized in this study have not yet been confirmed by 
immunostaining. Therefore, the confirmation of their presence in NIs needs to be carried 
out in the future. 
4.4.2 Study of NI proteins by an alternative approach 
Besides the “stacking gel approach" and “2D approaches" used in this study, other 
approaches can also be adopted to study NI proteins. For example, flow cytometry can be 
used to detect and isolate NIs (section 3.2.3), which can complement the present 
approaches to give a more complete list of the NI proteins and further confirm the results 
of the present study. The newly generated GFP-polyglutamine transgenic fly lines could be 
used in this method to facilitate the detection and isolation of NIs. 
4.4.3 Study of NI proteins using other polyglutamine fly models 
The present study mainly used M J D models for identification of NI proteins. However, 
other models could also be used such as S B M A , SCAl and the newly generated GFP-
polyglutamine models. As discussed previously, the different polyglutamine models 
express different polyglutamine disease proteins with different length of glutamine repeats. 
The SCAl model expresses the full-length human polyglutamine proteins, whereas M J D 
and S B M A models express the truncated human polyglutamine proteins. For GFP-
polyglutamine lines, they only express the naked polyglutamine peptide fused with GFP. It 
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has been suggested that the naked polypeptide was more toxic than the truncated and full-
length proteins (Zoghbi and Orr, 2000). The use of GFP-polyglutamine models would 
allow us to investigate a general effect of polyglutamine expansion, whereas other models 
overexpressing specific human polyglutamine disease proteins would give us insight into 
disease specific pathogenic pathways. 
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5. CONCLUSION 
The present study used a proteomic approach to study polyglutamine diseases in 
Drosophila. A typical cellular hallmark for most polyglutamine diseases is the formation 
of NIs, which has been shown to be critical to polyglutamine pathogenesis. According to 
the protein depletion theory, the depletion of cellular proteins into the NIs would 
undermine their activities and cause cellular disturbance, which may contribute to 
polyglutamine pathogenesis. Therefore, identification of NI proteins would provide us 
insight into the novel polyglutamine pathogenic pathways as well as open up new avenues 
to effective therapeutic interventions. 
Using the proteomic approach, 81 NI proteins have been identified from the present 
study. Most of them are newly identified NI proteins with diverse cellular roles in a wide 
range of cellular processes such as apoptosis, energy metabolism, signaling pathways, axon 
targeting, transcriptional regulation and protein folding. Some of these cellular processes 
had been previously implicated in polyglutamine pathogenesis such as induction of 
apoptotic pathways and impairment of energy metabolism, whereas most of them are novel 
pathogenic pathways. These pathways may act independently or interact with each other to 
cause cellular disturbance. The accumulation of cellular damage may eventually lead to 
neuronal dysfunction and cell death in polyglutamine diseases. 
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